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Nanoparticle enabled technology continues to attract heavy research interest and is 
increasingly used in many industries, including drug and medical device design. The research 
presented here focuses on applications of nano-materials in biomarker discovery and thin film 
sensors. In the first part, L-selectin (CD62L) protein is evaluated in bladder cancer patients as a 
possible biomarker for diagnosis and staging of the disease. The latter part employs inkjet 
printed nano-materials as QR codes for anti-counterfeiting applications. Additionally, an 
electrochemical sensor and a multi-well catalysis reactor are proposed, both incorporating inkjet 
printed nano-materials. 
Bladder cancer, while predominantly diagnosed at an early stage, has < 6% five-year 
survival rate when metastasized. Current FDA approved biomarker tests alone are unreliable for 
diagnosis. L-selectin, previously implicated as a biomarker, is quantified in human serum of 
bladder cancer patients, using semi-automated in-house microfluidic system with a bead-based 
electrochemical immunoassay. Calibration and good recovery is established for the 
immunoarray. Comparison to ELISA test reveals systemic errors in ELISA at low and high 
concentrations of the protein. Correlation of CD62L concentration in serum of cancer-free 
controls and bladder cancer patient with varying stages of the disease yields preliminary positive 
correlation. All cancer patients have high soluble CD62L concentration compared to healthy 
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cancer-free controls. Additionally, both ELISA and the new immunoarray can successfully 
differentiate low-grade and high-grade bladder cancer tumors. 
In the latter half of this thesis, zinc oxide nanoparticles are inkjet printed as a Quick 
Response code (QR code) on aluminum-coated integrated circuits. These optical phase tags 
provide improved anti-counterfeiting measures by adding a unique optical signature as an 
additional detection method. Compared to conventional barcodes and QR codes, zinc oxide 
material can be characterized with polarimetry and speckle pattern for analysis of material 
composition and surface roughness. These analytical tests are able to differentiate true and false 
class optical phase tags, even when minor non-compliance with the fabrication method is 
observed. Zinc oxide is doped with copper and nickel ions and 2D and 3D quilt patterns of these 
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  Chapter 1
Introduction 
1.1 Goals and Significance 
Richard Feynman, Nobel Prize-winning physicist and author of the memorable  
“Surely You’re Joking, Mr. Feynman!”, proposed the concept of nanotechnology in 1959. 
Nanotechnology has since become ubiquitous in modern life, from drug design and renewable 
energy applications to cosmetics and other household items. Nanotechnology-enabled global 
revenue surpassed $1 trillion in 20131 and continues to grow at a rapid pace. Medical 
applications alone, including drug design, delivery, and diagnostics market, contribute to over 
20% of this revenue.2 The National Nanotechnology Initiative (USA) has received over 
$1.2 billion in federal funding and invests heavily in research initiaves.3 Research output in 
nanotechnology is outpacing overall research output with over 400,000 publications between 
2010-2014 alone.4  
Nanotechnology has been harnessed in improving analytical platforms in a versatile 
manner, reducing the burden on resources by automating, miniaturizing, and simplifying 
components of the analytical device (see Figure 1.1).5 Automation is achieved by incorporating 
strategies such as on-line sample preparation protocols,6,7 synthesizing nano-materials for use 
with nano-volumes,8,9 and lab-on-chip micro/ nanofluidic devices.10,11 Utilization of pressure 
driven flows systems with nano-pumps have assisted miniaturization of analytical platforms.12,13 
Advances in synthesis of multifunctional nanomaterials, such as silica nanoparticles with 




Figure 1.1: Analytical platforms can be automated, miniaturized, and simplified to construct 
low-cost, high throughout devices. Combining these devices with the advanced computing 
allows for portable, wireless analytical devices.5 
 
steps. Combining these new systems with miniaturized detectors has led to construction of 
portable systems.14,15 Integration of these devices with wireless technology or portable 
computing stations allows for point of care (POC) analytical platforms.16,17 
Nanomaterials, in particular, have a unique advantage as their synthesis can be tailored to 
suit eventual application by tuning their properties, such as size, composition, surface 
modification, shape, and even assembly into larger structures, making them imminently suitable 
to different analytical chemistry platforms.18 These are currently used in various aspects of 
analytical chemistry processes, from their study as test molecules (small biomolecules, proteins, 
DNA/ RNA)5 to their utilization as analytical tools (optical tags, conductive inks)15,16. Some of 
 3 
the heavily commercialized applications of nanomaterials are in sample pre-treatment,19,20 
chromatography,8,21,22 and optical detection.23,24 Advancements in multi-functional surface 
modification of nanoparticles and device fabrication techniques, such as inkjet printing, has 
boosted development of lab-on-chip analytical devices.25 With miniaturization and portable 
analyzer components, several portable and POC devices have been developed for analysis of 
environmental pollutants, biological matrices, and food products.26  
POC devices provide rapid analytical alternatives to bulky, highly technical, and often-
costly analytical methodologies located at centralized laboratories.17,27 POC platforms often do 
not require technical training; in fact, many are specifically geared towards home usage, such as 
glucose monitoring systems or home pregnancy tests. In case of time-sensitive samples, the cost 
could increase substantially when conducting analysis by conventional methods as compared to 
portable technology. Simplification of analytical methods and miniaturization of device to make 
such devices portable often results in reduced sample preparation steps, lower required sample 
volumes, and greener methodologies; rigorous testing prior to field application ensures high 
analytical compliance and accurate testing. 
In this thesis, multiple aspects of sensor development incorporating nano-materials are 
explored. First, L-selectin protein is evaluated in serum samples from bladder cancer patients to 
establish a preliminary correlation between disease stage and protein concentration. Other works 
focus on inkjet printing nanoparticles to develop sensors with versatile applications. An optical 
tag is developed with Zinc oxide particles to aid in improved anti-counterfeiting measures. 
Preliminary studies are conducted into inkjet printing disposable electrode sensors with novel 
bronze conductive ink. Lastly, a design for multiplexed catalytic reactor, incorporating inkjet 
printed catalytic nanoparticles and 3D printed well plate reactor, is described. The thesis 
 4 
highlights the versatility offered by integrating nano-materials in analytical methodologies, both 
as analytes of interest and as analytical tools for sensing methodology. 
1.2 Discovery and Applications of Biomarkers 
A National Health Institute (NIH) working group in 2001 defined a biomarker as,  
“a characteristic that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”28 
The definition encompasses biological molecules, such as metabolites, hormones, proteins, 
RNA, or DNA, found in blood, urine, and other body fluids or tissues that indicate the presence 
of a disease. Two of the most well know tests for biomarkers include the home pregnancy tests 
and the glucose check test.17 In case of cancer, these markers differentiate an affected patient 
from one without the disease: Germline or somatic mutations, transcriptional changes,  
post-translational modifications, etc. are key causes of such changes.29 
The American Cancer Society predicts roughly 1.7 million new cases of cancers and 
609,000 deaths from cancer in the US, nearly 1670 deaths per day.30 According to the  
World Health Organization, cancer is the second leading cause of death worldwide accounting 
for roughly 15% of all deaths.31 Cancer patients have 50-90 % survival rate if it is caught at 
localized stage, compared to less than 30% when it is spread to lymph nodes or other organs, 
emphasizing the need for accurate early diagnostic tools.30 As tumors are hard to detect at early 
stages due to invasive biopsies required for confirmation, biomarkers can fill an important gap in 
clinical tests available. Cancer biomarkers can be a combination of biochemical changes, 
including gene expression, proteomic alterations, and metabolomics signatures.29 Biomarkers in 




Figure 1.2: Cancer biomarkers can be incorporated into clinical use from diagnosis to 
monitoring recovery. Examples of FDA approved biomarkers presently in clinical use, ranging 
from risk assessment, routine screening, diagnosis, determination of stage and prognosis, 
tracking response to therapy, and monitoring, are provided to exemplify the importance of cancer 
biomarker discovery.32 
 
non-invasively, however tissue markers require extensive biopsy or imaging for evaluation. 
The potential diagnostic applications in oncology exist at every stage of the disease and 
resulting therapy, including genetic or environmental risk assessment, diagnosis of disease, 
staging/ grading of cancer, tracking response to treatment (Figure 1.2).29 Establishing clinical 
relevance of a potential biomarker involves extensive evaluation and validation of analytical 
methodology, followed by assessment of clinical utility in a large patient sample pool (usually  
> 1000 samples) prior to establishing a routine clinical test. FDA has approved a few protein 
biomarkers for cancer diagnostics, such as HER2 for breast cancer and PSA for prostate cancer 
(Figure 1.2),32,33 while more are still being evaluated for clinical utility. Often these proteins are 
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found at elevated concentration in blood (with some exceptions) and are useful in disease 
detection prior to onset or detection of tumors; e.g. prostate specific antigen (PSA) blood test is 
recommended for older men as part of routine annual check as an early screening for prostate 
cancer. Some proteins however may be associated with multiple cancers, such as Interleukin-6 
(IL-6), necessitating the need for a panel of biomarker tests to establish clinical relevance. 
1.3 Protein Detection Platforms 
An array of analytical techniques is currently employed for protein detection. ELISA or 
enzyme linked immunosorbent assays are the gold standard for protein quantification and still 
heavily used for clinical testing. Analysis in ELISA relies on protein-antibody interactions, while 
other techniques such as flow cytometry, and bioimaging also employ similar interactions for 
analysis of different target biological media or organs. The main challenger to ELISA as a 
clinical analytical tool is liquid chromatography-mass spectrometry systems, a relatively new but 
rapidly expanding methodology. Our laboratory employs an electrochemical detection technique 
in a modified ELISA format, which aids more sensitive detection protocols. All of these 
techniques are briefly discussed here. 
1.3.1  Antigen-Antibody Interactions 
Antigens are foreign molecules that can induce an immune response in the human body. 
Some examples of external xenobiotic agents are pollutants, virus or bacteria particles, or even 
foreign protein matter. Antigens often present several epitopes on the surface of their body that 
are recognized by antibodies. Antibodies, also known as immunoglobulins (Ig, molecular weight 
~ 150,000 Da), are produced by the immune system to combat any potential diseases on 
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exposure to antigens. Heavy and light peptide chains form the Y-shaped glycoprotein of an 
antibody, as seen in Figure 1.3, with a crystallizable or constant region (Fc) and an antigen-
binding fragment (Fab).34 The Fc region binds to parts of the immune system, including 
lymphocytes. The Fab region recognizes the target antigen, through antibody-antigen interaction 
by binding to specific epitopes of the antigen. 
Antibodies are highly specific towards a certain antigen or even specific epitope of a 
given antigen. The antigen-antibody interactions are often through a combination of van der 
Waals forces, hydrogen bonds, hydrophobic, and electrostatic interactions, whereby the epitope 
fits into the binding pocket of the antibody.35 The antibody-antigen interactions occur with high 




Figure 1.3: Structure of antibody or immunoglobulin protein. The light chain contains multiple 
binding sites that can recognize specific epitopes on antigens, thus providing selectivity to 
immunoassays. 
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protein biomarkers, antibodies are commercially produced for specific recognition of target 
protein. Antibodies are generally available in monoclonal and polyclonal forms. The former 
recognizes a single epitope on the target protein, whereas the latter contains binding sites for 
multiple epitopes. ELISA utilizes either a single or a pair of antibodies for capture and detection 
protocols. The high specificity in antibody-protein interactions makes ELISA methodology 
uniquely selective for protein quantification. 
1.3.2 Enzyme-linked Immunosorbent Assay 
A ubiquitous assay for clinical protein quantification, enzyme-linked immunosorbent 
assay (ELISA) is a solid-phase assay for detection of peptides, proteins, antigens, and even 
hormones. In ELISA, detection is achieved by specific capture of a target protein with 
complementary detection antibody tagged with an enzyme label, followed by spectroscopic 
detection using a substrate-enzyme reaction.35 Commonly, horseradish peroxidase (HRP) or 
alkaline phosphatase (AP) are used as an enzyme label, while the choice of a substrate depends 
on detection mechanism, i.e. spectrophotometry, fluorescence, or luminescence.35 The assay is 
carried out in a 96- or 384- well format that has enables automation and commercialization of the 
assay.  
The primary ELISA formats in use can be categorized on basis of antigen capture method 
and detection method, as in Figure 1.4. Antigen can either be directly immobilized on the plate 
through physical adsorption (Figure 1.4A-B) or indirectly via capture antibody immobilized on 
the plate (Figure 1.4C). In each case an antibody, tagged with an enzyme label, is used for 
detection. In an indirect assay, a secondary antibody is captured on the detection antibody, the 





Figure 1.4: ELISA operational platforms include (A) direct, (B) indirect, and (C) sandwich 
assay. The sandwich assay, with surface bound capture antibody, is perhaps most commonly 
used as the gold standard in protein detection. 
 
“sandwich” format, where a primary (or capture) antibody (Ab1) specific to target protein is 
attached to the bottom of a well plate (Figure 1.4C). Samples containing the target protein are 
then added to the well and allowed to incubate for a specified time. Unreacted sample is removed 
via washing, followed by the incubation with the secondary (or detection) Antibody (Ab2). The 
secondary antibody is tagged with the enzyme label. Once incubation and subsequent washing is 
complete, a substrate chemical is introduced which on conversion by the enzyme produces 
optical output. Typically, a visible signal is produced and is read by a spectrophotometer. 
Commercially available ELISAs have low detection limits in picogram per milliliter (pg mL-1) 
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range, which can be improved to high femtogram per milliliter (fg mL-1) with use of fluorescence 
tags if needed.  
Several ELISA kits and automation systems are available commercially, as seen in  
Table 1.1. Some multiplex analyzers are commercially available (Table 1.1), capable of 
measuring up to 10 proteins simultaneously. Systems like Luminex (R&D systems), FirePlex 
(Abcam) employ fluorescence detection, while Roche Diagnostics or Mesoscale Discovery use 
electrochemiluminescence. Even surface plasmon resonance has been applied to ELISA based 
protein detection by Horiba Inc. and BIO-RAD. 
 
Detection method Multiplexing Automation Detection limit 
Commercial 
Suppliers 
Spectrophotometry Single No pg mL-1 Quantikine,
36 
SimpleStep37 
Spectrophotometry up to 8 Yes pg mL-1 Elysis38 
Fluorescence 20 - 75 Yes pg mL-1 Luminex,
39 
FirePlex40 
Electrochemiluminescence up to 10 No High fg mL
-1 




Resonance up to 6 No pg mL
-1 ProteOn42 
Table 1.1: ELISA platform has been commercialized in a versatile selection of assays, including 
single biomarker kits, automated multiplexed instruments. Introducing colorimetry, fluorescence, 
electrochemiluminescence, and even surface plasmon resonance detection techniques has also 
diversified its applications.  
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ELISA detection mechanism has been adapted to versatile biological sample detections: 
Protein attached to cell surfaces or present within cell too can be detected. Flow cytometry has 
been employed for cellular surface proteins, where detection antibodies with fluorescent tags are 
incubated with the sample.35 As cells with completed immunoassay pass the detection cell, the 
fluorescence from captured antibodies is quantified. Recently, intracellular proteins have been 
successfully detected with flow cytometry by rendering the cell membrane permeable and 
subsequently staining target proteins by fluorescent antibodies.43 Similar approach is used in case 
of in vivo imaging of target proteins: Fluorescent antibodies are injected into the test subject, 
which travel to areas containing the analyte. Imaging can potentially show protein distribution in 
organs aiding diagnosis of some cancers. 
ELISAs have consistently been used for clinical quantification of proteins and often yield 
reliable results, although they are time and labor intensive, and require large sample volumes. 
The latter is particularly disadvantageous when multiple proteins panels need to be screened.27 
Nevertheless, multiplexing requires expensive consumables and reagents, including chips and 
laser sources. The best commercially available alternative for simultaneous multi protein 
quantification with high sensitivity and specificity is mass spectrometry based proteomics.  
In research stages, an array of electrochemical protein detection techniques are investigated that 
offer a cheaper and more robust analytical platform. 
1.3.3 Electrochemical Detection platforms 
Electrochemical detection is a low-cost and robust alternative to ELISA methodology, 
suitable for developing portable devices without expensive equipment; electrical signals are also 
more suitable for electronic displays in POC device construction. The rapidly market integrated 
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handheld glucose meters, accounting for nearly 85% of the POC market44, use electrochemical 
detection methodology highlighting its robustness for such application. 
ELISA methodology has been simplistically adapted to electrochemical platforms by 
electrode surface modification with Ab1. The sandwich immunoassay is then developed on the 
electrode chips as in ELISA, however the enzyme is selected for an electrical output, in contrast 
to an optical output, on reaction with the substrate. Detection tracks changes in electrical 
parameters, such as impedance, conductance, potential, or current, the last two being easiest to 
incorporate into POC devices. HRP, one of the common ELISA enzyme labels, has  
well-established electrochemical reactions with multiple substrates.45 Other enzymes or 
substitute materials used for electrochemical immunoassays include AP, glucose oxidase, and 
conductive polymers.46  
HRP contains a single central heme group that readily undergoes catalytic 
oxidation/reduction in the presence of hydrogen peroxide (Scheme 1.1). Hydrogen peroxide 
oxidizes iron in the heme center to its oxidized form (FeIV=O), thus activating the enzyme. The 
enzymes can then be easily reduced at the electrode surface during reaction with the substrate. 
Multiple enzyme labels can be introduced on the sensor surface by incorporating nanoparticles 
with multiple surface-bound enzyme labels, thus amplifying signal generation and increasing 
assay sensitivity beyond conventional ELISA capabilities.46 This approach has been further 





Scheme 1.1: Electrochemical signal generation with HRP enzyme labels. HRP is readily 
oxidized at the heme center in presence of H2O2 (1) and is the reduced in the presence of a 
substrate such as hydroquinone (2). The benzoquinone generated in (2) can be reduced at the 
electrode surface generating a current (3). 
 
1.4 Nanoparticles in Electrochemical Immunoassays 
Nanoparticles have drawn attention for use in electrochemical assays due to the 
possibility of developing multi-label, multi-functional sensing molecules. Nanoparticles were 
however initially used to increase electrochemically active surface area of the electrodes in 
electrochemical immunosensors. As nanoparticles have high surface-to-volume ratios, 
researchers could achieve lower detection limits and higher sensitivity to reach clinically relevant 
concentration ranges.47 Dequaire et al48 first used gold nanoparticles bound to multiple detection 
antibodies in an electrochemical sandwich immunoassay, by measuring stripping voltammetry. 
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Newer approaches, while not focusing on stripping of the nanoparticles, have used metallic or 
polymeric nanoparticles, or quantum dots with multiple enzyme and antibody labels to amplify 
electrochemical measurements, including impedence, amperometry, and voltammetry, in 
modified ELISA platforms. As previously discussed attaching multiple enzyme labels to 
nanoparticles can greatly enhance the sensitivity: Wang et al49 were the first to use such 
bioconjugates for detection of DNA, wherein thousands of alkaline phosphatase and probe DNA 
were surface bound to multiwall carbon nanotubes to achieve femtomolar detection of IgG in 
buffer.  
Our research heavily employs nanoparticles, magnetic beads, single walled carbon 
nanotubes (SWCNs), for both electrode surface area enhancement and bioconjugate formation, 
in designing ultrasensitive electrochemical biosensors for cancer protein biomarkers.45,46,50,51 
Earlier, shortened single wall carbon nanotubes (SWCNs) have been self-assembled into an 
upright carbon nanotube “forest” from DMF solutions onto electrode surface pre-coated with 
thin iron oxide-Nafion layer.52,53 Antibodies are surface-bound by amide coupling using  
1-(3-(dimethylamino)propyl)-3ethylcarbodiimide hydrochloride (EDC) and  
N-hydrosulfosuccinimide (NHSS), as the SWCNs have end carboxyl groups. Antibody 
concentration on the electrodes increases 10-15 fold, leading to 10-fold signal increase during the 
electrochemical immunoassays.  
Alternatively, ~ 5 nm glutathione-protected gold nanoparticles have been used to increase 
electrochemically active surface area of screen-printed carbon electrodes and to introduce 
surface carboxyl groups, to which antibodies can be covalently bound through carbodiimide 
chemistry.45 The nanoparticles are coated on electrode surface through simple layer-by-layer 
assembly protocol.54 Additionally, magnetic particles decorated with protein detection antibodies 
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and HRP enzyme labels are used to introduce further signal amplification. The magnetic beads 
allow for sample purification as the bioconjugates can be washed after Ab2-protein conjugation 
prior to incubation with Ab1. These superparamagnetic beads range in size from 500 nm to  
50 µm, and provide a simple and inexpensive alternative to using nanoparticles. Further 
modification to assay protocol introduces use of biotin-antibodies and biotin-HRP labels with 
streptavidin-coated magnetic beads for rapid and reliable synthesis of such bioconjugates.45 
Similar electrochemical protocol has been adapted to analysis of L-selectin protein in chapter 2. 
1.5 Inkjet Printing 
Inkjet printing is a non-impact deposition technology, capable of printing a  
two-dimensional pattern with versatile selection of inks on multiple substrates. High level of 
commercial interest led to development of continuous and drop-on-demand inkjet printers, with 
both finding a niche for industrial applications. Inkjet or 2D printing relies on  
gravity-formed droplet deposition. Prototypes of earliest two-dimensional printers were 
developed and marketed during 1950s and 60s.55 With the innovation of drop-on-demand 
technology, and its adaptation to other media in 1970s and 80s, improved their potential for 
customized patterns, increasing range of their applications.56–58  
Presently, two-dimensional matrixes of drops are used to design thin films from organic 
compounds, inorganic particles,59 biomolecules,59 and polymers60 with versatile thermal,61 
electrical,50,62 optical63 properties. More recently, 2D printers have been adapted to construct  
3-dimentional scaffolds and structure with applications in pharmaceuticals,64 live tissues,65 and 
ceramics.66 
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1.5.1 Continuous printing 
In continuous printing, a stream of ink is broken into high-speed individual droplets by 
application of vibrations, as seen in Figure 1.5. Further downstream, droplets are selectively 
charged to control the droplet size (typically 20 - 150 mm)67 and trajectory towards the substrate. 
Unused ink is collected in a waste container, which may be recycled. Printing is performed with 
either uncharged or charged droplet streams in single-dot or multiple-dot printers respectively, 
the latter providing higher speeds of printing.55,68  
 
 
Figure 1.5: Schematic of continuous inkjet printing process. The ink droplets generated pass 
through a pair of high voltage deflection plates. A controlled droplet size moves on towards the 
substrate. Deflected ink droplets are collected and may be circulated for reuse. 
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This low resolution, but high-speed technology has found extensive use in printing labels 
in manufacturing, such as date, and time stamps. The adaptability of continuous inkjet printing to 
analytical and biological applications is limited. The reasons are two-fold: Cost and inflexible 
ink selection. The high equipment and maintenance cost, in addition to high volume of ink 
wastage prevents extensive implementation of this technology. More importantly, applications 
are reduced to inks that can be charged, while using volatile solvents. 
1.5.2 Drop-on-demand printing 
 Drop-on-demand (DOD) printing employs pressure pulses for “on-demand” droplet 
formation, replacing the charging and deflection systems used in continuous printing, as seen in  
Figure 1.6A. Thermal (Figure 1.6B)69,70 or piezoelectric (Figure 1.6C)56,71,72 element is used most 
frequently to achieve droplet formation. Other mechanisms in developmental stages use 
acoustic,73,74 electrostatic,75 electrohydrodynamic,76 and valve pressure pulses.77  
In contrast to continuous inkjet printing, droplets < 20 mm in diameter are achieved;55,78 
combining it with time controlled printing enhances the accuracy and resolution of this 
technology. Further, the removal of charging requirements expand applications of DOD printing 
to multi-functional inks, including polymers, biological materials, and ceramics. 
Thermal DOD printers use thermal evaporation of ink solvents for droplet formation. 
Heating up to 400˚C is achieved in ≤ 10 second timespan at a heating element in the path of ink 
flow. Solvent evaporation at the surface of this heating element forms an air bubble leading to 
ink droplet expulsion, see Figure 1.6B; fresh ink fills the chamber as the air bubble collapses.79 





Figure 1.6: Schematic for (A) a generic drop-on-demand inkjet printer. The pressure pulse 
device is commonly either (B) thermal or (C) piezoelectric. Drops are generated due to 
contracting and expanding vapor bubble or the flexing of a piezo-material in thermal and 
piezoelectric devices respectively. 
 
applicability in printing thermally sensitive inks and biological media. However, phase-change 
inks, low-melting salts can be printed consistently with thermal inkjet printers. 
Piezoelectric printing utilizes an expandable element of piezoelectric material, controlled 
by electric voltage ramps to generate pressure pulses required for DOD printing (Figure 1.6C). 
As the element expands on application of a voltage, an ink droplet leaves the holding chamber. 
The retraction to original shape by this element fills the chamber with fresh ink.79,80 This  
non-interactive, physical process of droplet formation in piezoelectric DOD printers makes them 
universally suitable to all types of inks. While the cost associated with piezoelectric element and 
software is high, the easy control over droplet size by variation in voltage, pulse length and 
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frequency, and the aperture of ink release has attracted considerable use in analytical and 
biological applications. 
1.6 Overview of Dissertation 
Sensor development encompasses versatile approaches in analytical chemistry, including 
biomarker discovery, sensor fabrication, and analysis. Each of these stages can use 
nanotechnology for tunable and customized approach leading to low-cost, yet accurate analytical 
platforms. This thesis aims to address the different aspects of sensor development through 
showcasing a few applications of analytical tools. Firstly, an existing electrochemical 
immunoarray methodology is adapted to the evaluation of CD62L protein in metastatic bladder 
cancer, with the goal of commenting on clinical relevance as a possible biomarker. Secondly, 
nanoparticles are used in multiple approaches utilizing inkjet printing for the development of thin 
film sensors, including construction of anti-fraud QR code, printing disposable sensors, and 
fabrication of a catalytic reactor.   
Chapter 1 introduces the contextual significance of the work completed, including the 
importance of nanomaterials in analytical chemistry research, portable sensor design, protein 
detection strategies, and inkjet printing technology. The chapter delivers the information needed 
to highlight the rational approach adapted to applications of nanomaterials in biomarker 
discovery and thin film sensors. The technologies detailed in this chapter provide a theoretical 
framework for the work presented in this dissertation. 
Chapter 2 details an adaptation of a well-established semi-automated microfluidic 
electrochemical immunoarray methodology towards the quantification of L-selectin protein in 
bladder cancer patients. The bead-based electrochemical immunoarray provides a sensitive, low 
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cost alternative to conventional immunosorbent protein assays, which is able to accurately 
quantify the protein in low-volume serum samples, while maintaining a low patient sample 
dilution factor. The results indicate the immunosensor to be more reliable than the gold standard 
ELISA. L-selectin shows distinct elevation in serum concentration for bladder cancer patients 
compared to cancer-free controls, suggesting possible clinical relevance as a biomarker. 
Chapter 3 concentrates on the development and fabrication of a chemical identification 
tag for the purpose of improved anti-fraud measures. Zinc oxide nanoparticles, in pure or doped 
solutions, with selective optical properties are inkjet printed in form of QR codes. These are 
analyzed by dispersion properties to classify true and false optical tags, providing an elegant 
solution to improve counterfeit detection methods. Inkjet printing these thin film sensors 
provides a low-cost approach to manufacturing that is adaptable to variety of printing substrates, 
as evidenced by the prototype prints on ICs. Possible applications include security tags on 
electronic components, therapeutics, and other high value materials.  
Chapter 4 introduces the application of inkjet printed to disposable thin-film 
electrochemical sensors and catalytic reactors. In part one, a novel bronze material is evaluated 
for its dispersive properties and possible utilization as a conductive ink for an electrochemical 
sensor. The parameters involved in substrate and ink optimization for inkjet printing these 
nanomaterials are discussed. Further work will include printing of the sensors, and evaluating 
their electrochemical performance. Part two details a design for well plate format 3D printed 
catalytic reactor that incorporates inkjet printed catalytic nanomaterials. Manganese oxide sol-gel 
materials with known catalytic properties are optimized for inkjet printing. An integrated inkjet 
and 3D printed reactor system is designed for multiplexed catalytic performance evaluation. 
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Further work will include printing of the prototype and evaluating its performance with simple 
electrocatalytic reactions. 
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  Chapter 2
Evaluation of Soluble L-Selectin in Bladder Cancer Patients Using a 
Microfluidic Bead-based Modified ELISA Assay 
2.1 Abstract 
A low-cost, sensitive bead-based electrochemical immunoarray is reported for soluble  
L-selectin (or CD62L protein), a potential biomarker for the staging of bladder cancer.  
A semi-automated modular microfluidic array is used with online antigen capture on 
superparamagnetic beads that are subsequently delivered to a detection chamber housing 
multiple sensors. The assay is designed to accurately detect CD62L in diluted serum with limit of 
detection (LOD) at 0.25 ng mL-1 and a dynamic range of 0.25 - 100 ng mL-1. The microfluidic 
array gives significantly better accuracy and higher sensitivity than a standard ELISA kit, which 
is shown to be subject to signficiant systematic error in high and low concentration ranges.  
41 serum samples, from patients with varying grades of bladder cancer and cancer-free controls, 
are analyzed by the immunoarray and ELISA and CD62L levels are correlated. This work 
establishes a new accurate assay for CD62L, and highlights the potential of this protein in serum 




2.2.1 Bladder cancer: Statistics and Stages 
Bladder cancer arises from the urothelium, presenting as non-invasive disease in majority 
of patients (Figure 2.1). 2018 will see nearly 81,000 newly diagnosed cases and ~17,200 deaths 
from bladder cancer, according to the American Cancer Society.1 Four times more prevalent in 
men than women, bladder cancer occurs at the median diagnosis age of 65 years.1 Bladder cancer 
tumors are categorized as high- or low-grade tumors, both having a high risk of recurrence. 
High-grade tumors additionally have a higher risk of invading the muscle wall of the bladder, 




Figure 2.1: Bladder cancer presents at the urothelium of human bladder. Staging of the disease 
is based on tumor growth from the bladder lining outwards into the muscle wall and beyond. 
(Figure adapted from reference 2) 
 29 
five-year survival rates with stage of disease. In more than 70% of patients, bladder cancer will 
reoccur within 2 years of remission,3 making long-term monitoring with non-invasive biomarker 
test key to improving patient outcomes.  
Bladder cancer is staged based on growth of the tumor into wall of the bladder, as shown 
in Figure 2.1.4 At stage 1, the tumor may be present in the bladder lining and the connective 
tissue, without breaching into the muscle layer. As the tumor grows into the muscle layer of the 
bladder, the tumor is classified as stage 2. Stage 3 indicates the cancer has grown into the fatty 
tissue, the prostate, uterus or vagina, and local lymph nodes. At stage 4, cancer may have gown 
into the pelvis or abdominal wall, nearby organs, or even fully metastasized to local and distant 
lymph nodes. Non-invasive tumors (stage 1 and 2) have five year survival of ~88% whereas 
locally advanced/metastatic disease have a poorer prognosis with only a 6% survival rate.5,6 
While about 50% tumors are detected at stage 1, the low outcomes at later stages highlight the 
need for diagnostic molecular tests. Tumor biomarkers are not yet clinically employed for 
determination of a patient’s progression, prognosis or treatment, and there are no molecular 
forecasters for high grade disease or metastatic potential in bladder cancer cases.1,7,8 
2.2.2 Current Detection Strategies 
Currently, Bladder cancer is detected with a combination non-invasive and invasive test: 
They include urinalysis, voided urine cytology (VUC), cystoscopy, biopsy, biomarker tests, and 
imaging studies, Figure 2.2.9 The efficiency of such tests varies greatly based on knowledge of 
patient habits and their risk of developing bladder cancer. At present, no routine screening test is 
available for bladder cancer. Early detection of bladder cancer is often due to appearance of 





Figure 2.2: Detection strategies for bladder cancer. Early detection tools include urinalysis, 
voided urine cytology (VUC), cystoscopy, and biomarker test, such as UroVysionTM, NMP22, 
etc. Biopsy and imaging tests are used to confirm and stage the disease.  
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urination, etc. Urinalysis, a common screening test, can check for any abnormal physical or 
biochemical urine characteristics, such as pH, elevated cell count, blood composition in urine, 
etc.10 The test strips provide only qualitative measure of anomalies in urine (Figure 2.2). 
Although non-invasive and easily accessible, such changes in urine can also result from 
infections or other health conditions; thus urinalysis is not used as a routine screening test for 
bladder cancer. 
If bladder cancer is suspected from urinalysis — due to risk factors in patients that 
include birth defects, chemical exposure, or previous occurrence of cancer — VUC and 
cystoscopy are performed. VUC is a non-invasive test that microscopically examines urine for 
the presence of possible cancer cells, such as clumps of cells seen in Figure 2.2. 
Early stage and low-grade tumors rarely shed cancer cells into the urine, limiting VUC to 
detection of primarily high-grade, late stage tumors.9 Nevertheless, VUC is a high accuracy,  
non-invasive confirmatory test for bladder cancer.  
In cystoscopic procedures, a cystoscope, a thin hollow tube with a camera, is inserted into 
the bladder to visually examine lining of the bladder and the urethra for anomalies (Figure 2.2). 
Skill level and cost (due to anesthesia) are at times prohibitive factors in successful detection of 
bladder cancer. Due to high risk of recurrence, bladder cancer patients undergo checkups 
quarterly in the first two years of remission and thereafter semi-annually, making patient 
discomfort particular disadvantageous to the use of this invasive procedure. On observing 
abnormal cell lining during cystoscopy, the physician will collect samples for biopsy. As with 
any cancer biopsy, results may be conclusive and confirmatory or inconclusive due to tissue 
heterogeneity and skill of the physician in recognizing abnormal bladder lining.9,11,12 In case of 
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bladder cancer, biopsy is also used to assess spread of cancer and its grade, i.e. low- or high-
grade. 
FDA has additionally approved multiple POC devices and biomarker tests for bladder 
cancer; these include UroVysionTM, bladder tumor associated antigen (BTA) test, Immunocyt, 
NMP22 (BladderChek®).10 UroVysionTM, manufactured by Abbott molecular, is a urine-based 
genetic biomarker test that uses fluorescence to detect aneuploidy, an unusual number of 
chromosomes in cells, in certain chromosomes.13 Although with low false negative rate, similar 
to VUC this test can only detect cancer if minimum threshold of cells are present in urine and 
only if cancer is present with the target genetic changes. BTA test is a single step lateral flow 
device based on colorimetric detection of tumor-associated antigen hCFHrp (human complement 
factor H-related protein). The test has moderate specificity at 50 - 85%, however has a high false 
positive rate lowering its predictive value to < 20%.14 ImmunocytTM (DiagnoCure Inc., Canada) 
is a fluorescence biomarker test measuring two mucin-like antigens and carcinoembryonic 
antigen. Immunocyt has low positive predictive value at 26%, but researchers have suggested 
delaying cystoscopy based on negative Immunocyt results due to the high negative predictive 
value of 93% observed.15 NMP22 antigen test is available as ELISA kit or as POC device 
BladderChek® (Abbott), and assays nuclear mitotic apparatus protein 1 (NUMA1) with 
sensitivity and specificity at 56% and 88% respectively.16 Like Immunocyt, negative NMP22 test 
has been used to delay cystoscopy in patients with recurring bladder cancer. 
All biomarker tests have a low false-negative rate and are thus used primarily to confirm 
absence of cancer in patients in remission or those with recurring tumors. Nevertheless, in 
monitoring new and surviving patients, these tests cannot stage and grade bladder cancer tumors. 
Imaging techniques, which include computed tomography (CT scan), magnetic resonance 
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imaging (MRI), and positron emission tomography (PET scan) are principal tests for staging and 
grading tumors.9 A CT scan takes X-ray images, after a contrast dye is injected into the patient, 
to recreate 3-dimensional images of tumors in the bladder or at lymph nodes (in case of 
metastasis). MRI, much like CT scan, uses a specialized contrast medium with magnetic fields 
for imaging tumors or enhanced lymph nodes. PET scans, used in isolation or with CT scans, 
image tumors after injection of a radioactive dye. The dye is selectively absorbed by cancer cells, 
providing much cleaner images; early indications suggest it may be more effective in assessing 
spread of bladder cancer than CT or MRI scans. Additionally, ultrasound — a technique that 
uses sounds waves without a contrast dye — can be employed to detect spread of bladder cancer 
to kidneys and rest of the urinary tract. Doctor's skill in staging and grading tumors from these 
images is perhaps critical to patient outcomes as survival rates decline rapidly in late stage 
bladder cancer. 
2.2.3 Microfluidic System for Electrochemical Immunoassay 
We have developed high sensitivity microfluidic protein immunoassays (also referred to 
as “immunoarray”) with modular semi-automated microfluidics and labeled detection beads.17 
Our microfluidic system (Figure 2.3A) consists of low-cost in-house reaction chamber  
(Figure 2.3B) and detection chamber (Figure 2.3C), assembled downstream from a pump, 
injector, and switching valves.18 The pump drives the flow for the entire system, usually at flow 
rates of 0.1 - 1 mL min-1. The injector delivers 100 µL of magnetic beads, analyte samples, and 
sensing solution by manual injection. Switching valves allow control over directionality of flow, 








Figure 2.3: An in-house microfluidic system (A) for electrochemical immunoarray consisting of 
a pump, injector, switching valves, reaction chamber (B), and a detection chamber (C). The 
antigen and detection beads are stirred in reaction chamber (B) for incubation of antigen and 
detection antibodies. The electrodes, on which the immunoassay is completed by incubation with 
primary antibodies, are housed in the detection chamber (C) and connected to an electrochemical 
station and a computer for data capture and analysis. 
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detection chamber in a sequence. PEEK tubings and leuers complete all fluidic connections 
between the various components. 
The reaction and detection chamber are fabricated by casing a molded 
poly(dimethylsiloxane) (PDMS) channel between two poly(dimethylmethacrylate) (PMMA) or 
polycarbonate plates. The PDMS channels regulate the volume of each chamber and provide a 
leak-proof channel. The reaction chamber has an oval PDMS channel (~ 100 µL in volume) that 
contains a magnetic stir bar. The top PMMA plate of reaction chamber has two machined 
openings for an inlet and an outlet (Figure 2.3B); the bottom PMMA plate provides a flat support 
surface to the assembly. The reaction cell sits atop a magnetic stirrer allowing stirring of 
contained solution during the immunoarray. In our protocol, magnetic beads (MB) are first 
injected into the system and captured in the reaction chamber while holding a magnet on top of 
the chamber (Figure 2.3A). The analytical sample is then injected and flow is stopped as the 
sample reaches the chamber. The two are then stirred for a fixed amount of time to facilitate the 
reaction between detection beads and the antigen (Ag).  
The detection chamber has a narrow rectangular PDMS channel (~ 60 µL) that can 
encase the 8-electrode reaction spots. Like the reaction chamber, the detection chamber’s top 
plate also has an inlet and outlet for the flow. Additionally, the plate has grooves on either side of 
the inlet and outlet line housing a silver/silver chloride (Ag/AgCl) reference electrode and 
platinum (Pt) counter electrode (Figure 2.3C), such that these lie above and below the 
8-electrode sensor reaction spots. The reacted solution is transferred from the reaction chamber 
to the detection chamber, where the immunoarray is completed and electrochemical detection is 
performed. 
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2.2.4 Scope of Current Research 
Recent research has been directed at understanding the biological process involved in 
cancer progression to improve targeted and personalized therapy. Several molecules from the 
lymphatic system are being studied for correlation with metastasis in cancer cases.19–21 Selectins, 
a class of mammalian vascular adhesion molecules, are some of such biomolecules.22–27 
Specifically, L-selectin (or CD62L), expressed on a variety of inflammatory cells, plays a crucial 
role in migration and homing of lymphocytes to lymph nodes.28–30 A previous study shows a 
marked increase in gene and cellular expression of L-selectin in muscle-invasive high-grade 
bladder cancer tumors in cell lines and in human tissues, and suggests a potential role of CD62L 
as a biomarker for metastatic bladder cancer.7 A more sensitive and accurate technique than 
standard enzyme-linked Immunosorbent assay (ELISA) for serum protein quantification could 
lead to better diagnoses to direct treatment plans.  
Our approach utilizes magnetic beads massively labeled with detection antibodies (Ab2) 
and horseradish peroxidase (HRP) capture target proteins (i.e. detection beads) that are delivered 
to an amperometric sandwich immunoassay detection chip, providing a fast, low-cost alternative 
to ELISA and other commercial protein tests.31–33 Versatility and accuracy of this approach has 
been demonstrated by ultrasensitive multiplexed detection of cytokines,17,18,34 prostate specific 
antigen (PSA),35 and other protein and peptide biomarkers36–38 at fg mL-1 levels in human serum.  
In this chapter, an adaptation of this immunoarray is presented, wherein the number of HRP 
enzyme labels on the magnetic bead bioconjugate are optimized to measure circulating CD62L 
protein at clinically relevant levels. Limit of detection (LOD) is obtained at 0.25 ng mL-1 and 
excellent sensitivity with log-linear dynamic range of four orders of magnitude is seen in the  
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pg mL-1 to ng mL-1 range for CD62L. Accuracy is demonstrated by multiple validation 
experiments, and serum samples from cancer-free and bladder cancer patients are analyzed. The 
immunoarray is observed to be more sensitive and accurate than a standard CD62L ELISA kit, 
and serious systematic errors in the latter approach are identified. Preliminary results suggest that 
the microfluidic serum immunoarray can differentiate between cancer-free and bladder cancer 
patients (diagnostic sensitivity = 93.6%, specificity = 100%) and between patients with  
low-grade and high-grade lesions (sensitivity = 90%, specificity = 91%). 
2.3 Experimental 
2.3.1 Chemicals and Instruments  
Screen-printed 8-electrode carbon array (700 µm diameter) sensors are purchased  
from Kanichi Research Services Ltd (Manchester, England). L-glutathione reduced 
(GSH, ≥98%), gold (III) chloride trihydrate (HAuCl4·3H2O, ≥99.9%), sodium borohydride 
(NaBH4, 99%), poly(diallydimethylammonium chloride) (PDDA, MW 200,000-300,000, 20% in 
water), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC), 
N-hydroxysulfosuccinimide (NHSS), bovine serum albumin (BSA), calf serum, Tween-20, 
sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic (Na2HPO4, ≥98%), 
sodium phosphate monobasic monohydrate (NaH2PO4·3H2O, ≥98%), hydroquinone (HQ, 
≥99%), hydrogen peroxide (H2O2, 30%) are purchased from Sigma-Aldrich (St. Louis, MO, 
USA). The polydimethylsiloxane (PDMS) kit is obtained from Dow Corning (Auburn, MI, 
USA). Streptavidin-coated superparamagnetic beads (MP, 1 µm Dynabeads) and biotinylated 
horseradish peroxidase (HRP, 2.5 mg mL-1) are purchased from Life Technologies (Carlsbad, 
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CA, USA). All solutions are prepared using 18 MΩ·cm water purified by passing house-distilled 
water through a Hydro Service and Supplies purification system (Durham, NC, USA).  
Monoclonal anti-human L-Selectin (CD62L) antibody (Ab1, Catalog Number: BBA24, 
Clone: 4G8), biotinylated anti-human L-Selectin antibody (Ab2, Catalog Number: BAF728), 
recombinant human L-Selectin/CD62L protein antigen (Ag, Catalog Number: ADP2), and 
Human sL-Selectin/CD62L ELISA kit (Catalog Number: BBE4B) are purchased from R&D 
Systems (Minneapolis, MN, USA). Human serum samples are collected from patients at the 
University of Connecticut Health Center (UCHC). Upon approval from the IRB and Written 
Informed Consent from patients, sample collection is completed. All samples are stored at or 
below -80°C until use. Absorbances are measured for each assay experiment using FlexStation 3 
multi-mode microplate reader (Molecular Devices, Sunnyvale, CA, USA). CHI 1040C 
multipotentiostat electrochemical workstation (Austin, TX, USA) is used for 8-channel 
amperometric detection. 
2.3.2 Fabrication of Immunoarray Sensor 
Screen-printed 8-electrode carbon array sensors are fabricated with layer-by-layer (LBL) 
assembly as previously described. Briefly, arrays are coated with successive layers of polycation 
PDDA and negatively charged 5 nm glutathione-coated gold nanoparticles (GSH-AuNPs) using 
LBL electrostatic adsorption for 20 min each as previously reported and as illustrated in Figure 
2.4. Incubating a freshly prepared crosslinking solution of EDC and NHSS for 10 min activates 
terminal surface carboxyl groups on the GSH-AuNP layer. The electrode sensor arrays are 
subsequently spotted with primary or capture antibody (Ab1), which is allowed to incubate 





Figure 2.4: Protocol for layer-by-layer assembly introducing capture antibodies on electrode 
surface. Initial layers of PDDA, glutathione gold nanoparticles are coated by physical absorption. 
The antibodies are then covalently bound to the carboxyl groups on gold nanoparticles by 
carbodiimide chemistry using EDC/ NHSS. 
 
Furthermore, prior to utilizing, the arrays are blocked with 2% BSA in PBS for 1 hr at 4°C to 
inhibit non-specific binding (NSB). 
2.3.3 Preparation of Bioconjugates 
A previous protocol is implemented for the attachment of numerous biotin-Ab2 and 
biotin-HRP labels to 1 µm diameter streptavidin-coated superparamagnetic beads (MPs,  
10 mg mL-1), as seen in Figure 2.5. Briefly, MPs are magnetically separated using an Invitrogen 
DynaMag spin magnet and subsequently washed with PBS pH 7.4 three separate times. Then 
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simultaneously biotin-Ab2 and biotin-HRP are added into the MP dispersion containing  
0.1% BSA in PBS pH 7.4 at a ratio of 1:2:4:4 (MP:Ab2:HRP:BSA) followed by incubation at 
37°C for 30 min. After conjugation, the bead bioconjugate (MP-Ab2-HRP, Figure 2.5) dispersion 
is magnetically separated and washed three distinct times with 0.1% BSA in PBS pH 7.4 to 
remove any excess Ab2 and HRP. Lastly, the bioconjugate is reconstituted with 0.1% BSA in 





Figure 2.5: MB-Ab2-HRP bioconjugates, used as the detection assembly, are prepared by 
incubating washed streptavidin coated superparamagnetic beads with biotin-Ab2 and  
biotin-HRP with 0.1% BSA in PBS buffer in 1:2:4:4 ratio. After 30 minute incubation at 37°C, 
the beads are washed and stored in 0.1% BSA in PBS at 4°C until used. 
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are determined, characterization assays are completed. Specifically, bioconjugate particles 
originally had 3,200 (± 300) Ab2 per MP and 10,000 (± 500) HRP per MP. After optimization for 
higher dynamic range, new concentrations used are 0.5 mg mL-1 HRP, 100 mg mL-1 Ab1, and 10 
mg mL-1 Ab2 (Figure 2.6). The new bioconjugate had on average 2,100 (± 200) Ab2 per MP and 
5,000 (± 400) HRP per MP labels, as measured by bicinchoninic acid assay (BCA) kit (Thermo 
Scientific, Rockland, IL, USA)39 and 2,2’-azino-bis(3-ethylbenzthiazoine-6-sulfonic acid) 
(ABTS) end-point assay (Sigma Aldrich, St. Louis, MO, USA)40. Absorbances are measured for 
each assay experiment using FlexStation 3 multi-mode microplate reader (Molecular Devices, 
Sunnyvale, CA, USA).  
2.3.4 On-line Capture and Detection Protocol 
An established modular on-line protein capture microfluidic system is employed, as 
shown in Figure 2.3A; this system provides a semi-automated methodology for protein detection. 
Previously published immunoarray procedure is used. Briefly, the system is first subjected to a 
flow of water followed by PBS-Tween 20. The detergent solution is used to minimize adhesion 
and NSB of undesirable molecules. Once the fluidic system is washed, 50 µL of bioconjugate 
(MP-Ab2-HRP) is added to 150 µL of 20 mM PBS pH 7.4. This bioconjugate dispersion is then 
loaded into a 100 µL sample loop, injected at 100 µL min-1, and allowed to fill the capture 
chamber. Next, protein Ag (standard or patient sample) in diluted calf serum is loaded and then 
injected into the capture chamber. Once the capture chamber is filled, stirring within the chamber 
is allowed for 30 min to facilitate protein capture (Figure 2.3A). Throughout both sequentially 
injections, a magnet bar is held atop the capture chamber to ensure MP-Ab2-HRP are captured.  
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After the 30 min incubation period, resultant protein Ag-MP-Ab2-HRP bioconjugates are 
transferred to the detection chamber, which houses a CD62L Ab1 modified 8-electrode 
immunoarray, by switching the valves in the proper direction and pumping PBS-Tween 20 at 
100 µL min-1 carrying the protein Ag-MP-Ab2-HRP into the detection chamber. The flow is 
stopped once the red-brown color of MPs filled the entire channel; this provides an indication the 
transfer process is complete. Bioconjugates incubated at the electrode surfaces for 15 min to 
allow efficient capturing and completion of the immunoarray sandwich, Figure 2.3A).  
PBS-Tween 20 flow is resumed to remove any unbound bioconjugates followed by further 
washing with hydroquinone (HQ) for production of an electrochemical background signal. 
Amperometric detection is completed at -0.2 V vs. Ag/AgCl by injecting a sensing solution of 1 
mM HQ mediator and 0.1 mM hydrogen peroxide (H2O2) at 100 µL min-1 into the detection 
chamber via the sample loop to activate the HRP labels on the bioconjugates. Prior to detection, 
the 8-electrode sensor array, platinum (Pt) counter, and Ag/AgCl reference are connected to a 
CHI 1040BC multipotentiostat (Figure 2.3A). An electrochemical redox-cycle yields 
amperometric current signals proportional to concentration of protein analyte (see Scheme 1.1). 
Once electrochemical detection is complete, a fresh modified 8-electrode array is inserted into 
the detection chamber for incubation of the next sample, which is undergoing protein capture 
during prior detection. 
2.3.5 Optimization of Enzyme Label 
Enzyme labels densely attached onto MP bioconjugates are optimized prior to finalizing 
CD62L protein antibody concentrations. This critical optimization step permits extension of the 
dynamic range from pg mL-1 to ng mL-1. In particular, four different sets of MPs with varying  
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concentrations of biotin-HRP labels, specifically 0.25, 0.5, 1.25 and 2.5 mg mL-1, and a constant 
concentration of Ab2 are prepared. Following preparation, assays are performed by injection of a 
control (0 ng mL-1), low (1 ng mL-1), and high (10 ng mL-1) antigen sample for each respective 
biotin–HRP concentration. As observed in Figure 2.6A, 0.5 mg mL-1 biotin–HRP provides the 
greatest signal difference between low and high concentrations; therefore, 0.5 mg mL-1 is utilized 





Figure 2.6: Optimization results for CD62L sandwich immunoarray performance upon 
employing standard concentrations of 0, 1 and 10 ng mL-1. (A) Optimization of Biotin-HRP 
using consistent Ab1 and Ab2 concentrations. Optimal concentration of biotin-HRP is determined 
to be 0.5 mg mL-1. (B) Optimized result for secondary antibody (Ab2) using consistent Ab1 and 
biotin-HRP label concentrations. Optimal concentration of Ab2 is determined to be 10 mg mL-1 
and (C) Optimized outcome for primary antibody (Ab1) using consistent Ab2 and biotin-HRP 
label concentrations. Optimal concentration of Ab1 is determined to be 100 mg mL-1. 
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2.3.6 Optimization of Antibodies for Protein CD62L 
In addition to enzyme label, the capture antibody (Ab1) and detection antibody (Ab2) 
bound on the immunoarray platform and MP bioconjugate respectively are optimized to achieve 
maximum signal sensitivity prior to execution of a standard calibration curve. First, the detection 
antibody is optimized. In particular, the concentration of HRP and Ab1 are kept constant and MP 
bioconjugates are prepared with three different Ab2 concentrations, specifically 5, 10 and  
20 µg mL-1. Subsequently, assays are performed by injection of a control (0 ng mL-1), low  
(1 ng mL-1), and high (10 ng mL-1) antigen sample for each respective bioconjugate 
concentration and amperometric current signals are compared. The optimum concentration of  
10 µg mL-1 Ab2 is selected, as shown in Figure 2.6B.  
The concentration of the primary antibody is crucial as this improves assay sensitivity 
and minimizes NSB. Therefore, arrays with varying concentrations of Ab1, specifically 5, 20, 
and 100 µg mL-1, are prepared and the immunoassay is completed by the aforementioned 
procedure. During this Ab1 optimization process, Ab2 and biotin–HRP concentrations are kept 
constant. After comparison between each of the amperometric current signals, 100 µg mL-1 Ab1 
is selected and employed as the optimum concentration, as indicated in Figure 2.6C. Therefore, 
the best immunoarray performance is obtained when 100 µg mL-1 Ab1 is bound on the sensor 
surface, while 10 µg mL-1 Ab2 and 0.5 mg mL-1 biotin–HRP are attached to the MP 
bioconjugates. These conditions are employed for all latter experiments. 
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2.3.7 Patient Sample Analysis and Data Processing 
After method optimization and accuracy validation, 41 serum samples from pateints with 
varying stages and grades of cancer are analyzed using the immunoarray procedure detailed 
above as well as ELISA kit BBE4B from R&D Systems. Samples (5 µL) are diluted 100-fold in 
PBS (pH 7.4) to bring CD62L levels into the dynamic range of the assay. Statistical analyses 
including box plots and receiver operating characteristic (ROC) analyses are done using 
MedCalc software. 
2.4 Results 
2.4.1 Optimization of Dynamic Range 
Soluble CD62L protein in human serum is previously reported at 0-700 ng mL-1 in 
cancer-free control subjects, and at 500-2000 ng mL-1 in lymphoma patients based on results 
from standard ELISA. For the bead-based microfluidic immunoassay, a standard calibration 
curve for protein CD62L is first prepared under conditions for highest sensitivity using 3,200 
(±300) Ab2 and 10,000 (±500) HRP per MP. Typical amperometric peaks (Figure 2.7A) under 
these conditions give a semi-log calibration plot with dynamic range of 4.9 to 625 pg mL-1  
(Figure 2.7B). 
Although high sensitivity is achieved (slope 61.3 ± 4.8 nA log[CD62L, pg mL-1])-1), 
patient sample dilutions of >10,000-fold are needed to remain within the dynamic range which 
could lead to serial dilution errors. To avoid high dilution, we decrease the number of HRP labels 
on the magentic beads. Biotin-HRP concentration during attachment to the beads is decreased 






Figure 2.7: Calibrations using protein CD62L standards in 5-fold diluted calf serum with 
amperometric detection using 1 mM HQ and 0.1 mM H2O2 at -0.2 V vs. Ag/AgCl. (A) High 
sensitivity calibration peaks and (B) Calibration graph with dynamic range from 0.25 ng mL-1 to 
100 ng mL-1. (C) Calibration peaks for assay adapted to clinical range and (D) Calibration graph 




these conditions is established in the ng mL-1 range, with detection limit 0.25 ng mL-1. The  
log-linear dynamic range extended to 100 ng mL-1 (Figure 2.7C-D). Good reproducibility is 
signified by small error bars (n=8). Furthermore, excellent sensitivity with slope of calibration 
plot at 33.9 nA ± 1.3 (log[CD62L], ng mL-1)-1 and R2 ≥ 0.98, as revealed in Figure 2.7D, are 
achieved in 30 min assays. The calibration is observed to be reproducible day-to-day with good 




Figure 2.8: Amperometric signals to demonstrate assay reliability and stability. (A) Current 
signals from four independent days for 0, 1, and 10 ng mL-1 CD62L. (B) Comparison of current 
signals indicating stability of surface bound Ab1 on the LBL sensor array over duration of one 
week for 0, 1, and 10 ng mL-1 CD62L. 
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2.4.2 Assay Validation using Spiked Calf Serum Samples 
Serum is spiked with different concentrations of pure CD62L and analyzed for validating 
accuracy of the immunoarray. Since human serum contained high levels of indigenous protein 
CD62L, calf serum is consequently used as a surrogate.  Calf serum is spiked at 75, 250, 350, 
550, 700, 1500, 3000 and 5500 ng mL-1 and diluted 100-fold with PBS pH 7.4 prior before 
assays to replicate the patient sample protocol. The recovery amongst the eight spiked samples is 
within 83–116% for the immunoarray system (Figure 2.9A-B), which falls within acceptable 
analytical limits. However, ELISA yields varying concentration-dependent recoveries within  
37–97%, as displayed in Figure 2.9A-B. With spiked levels as true values, these data show that 
the immunoarray method provides good accuracy in the 75-5500 ng/mL range, but that the 
ELISA kit has large errors above 1500 ng/mL and below 350 ng/mL CD62L.  
Correlation plots show that ELISA recovery vs. true spiked levels yields a slope of  
0.45 ± 0.03 (Figure 2.9C), well below the perfect correlation slope of 1, suggesting a general 
underestimation of CD62L by ELISA. For immunoarray results vs. true spiked levels  
(Figure 2.9D), a slope of 1.01 ± 0.02 with y-intercept at 0.13 ± 0.47 is found indicating excellent 
correlation with the actual CD62L levels and confirming accuracy of the assay. 
Further statistical treatment confirms this bias in ELISA kit. A one sample mean t-test is 
performed for individual spiking levels, for each detection method.41 Lower and upper 
concentration limits at 95% CI are calculated for individual recovery levels, as shown in  
Table 2.1. The detection method under consideration is accurate if the corresponding true spiked 
level is within the calculated range (For example, 75 ng mL-1 lies within the limits of 53.26 - 




Figure 2.9: (A) Comparison of Immunoarray and ELISA results with known spiked levels of 
CD62L standards in calf serum, at 75, 250, 350, 550, 700, 1500, 3000, and 5500 ng mL-1. 
Recovery is observed to be within 83%–116% for the Immunoarray and 37–97% for standard 
ELISA. (B) Zoomed inset for spiking levels 75 to 550 ng mL-1. Correlation plots for (C) ELISA 
and (D) Immunoarray vs. spiking CD62L level showed immunoarray  (slope = 1.01) is more 
accurate than ELISA (slope = 0.45). ELISA underestimates concentration above 1500 ng mL-1 



















at 95% CI 
75 53.26 – 97.44 no diff. 18.95 – 35.97 Sig. diff. Sig. diff. 
250 201.1 – 304.8 no diff. 169.7 – 221.9 Sig. diff. Sig. diff. 
350 249.0 – 425.4 no diff. 121.2 – 493.2 no diff. no diff. 
550 555.9 – 641.9 no diff. 290.4 – 623.4 no diff. Sig. diff. 
700 565.0 – 739.4 no diff. 578.6 – 784.8 no diff. no diff. 
1500 1008 – 1844 no diff. -280.0 – 2333 no diff. no diff. 
3000 2722 – 3763 no diff. 601.7 – 2250 Sig. diff. Sig. diff. 
5500 4305 – 6681 no diff. 921.4 – 4465 Sig. diff. Sig. diff. 
Table 2.1: Sample mean t-tests for spiked sample recoveries from Immunoarray and ELISA 
performed to determine the accuracy of each analytical method. Two sample mean t-test is 
performed between Immunoarray and ELISA recoveries. ELISA is found to underperform 
outside the concentration range of 350 - 1500 ng mL-1. 
 
* represents two sample mean t-test analysis for the null hypothesis, ELISA recovered   
   concentration = Immunoarray recovered concentration  
sig. diff. represents significantly different based on tstatistical > tcritical or P < 0.05 






From Table 2.1, we conclude that significant bias exists outside the concentration range 
of 350 - 1500 ng mL-1 for ELISA. Such trend is not observed for our method; specifically the 
immunoarray detection method yields recovery concentrations statistically similar to true spiked 
levels at 95% CI at all spiked levels.  
Furthermore, immunoarray and ELISA methods are compared using the two sample 
mean t-test (Table 2.1).41,42 Specifically, in our case, null hypothesis is set such that ELISA 
recovery = immunoarray recovery. Statistically relevant differences exit in recoveries if tstatistical > 
tcritical (P < 0.05). Upon analysis, we concluded that good correlation exists for the CD62L range 
of 350-1500 ng mL-1, with exception of 550 ng mL-1 (Table 2.1). These results indicate better 
accuracy of the immunoassay over the ELISA method, and reveal large systematic errors at the 
low and high concentration ranges for the ELISA kit. 
 Additional statistical analysis of correlation plots for spiked sample analyses provide 
further information on the accuracy of ELISA method. A slope of 1.0 and y-intercept of 0 ± 3SD 
indicates that analytical methods correlate very well, i.e. recoveries from both methods would be 
statistically similar. Verification of statistically relevant differences in slopes is performed by 
linear regression t-tests at 95% confidence interval (CI), see Table 2.2.42 Recovered 
concentrations are utilized and tstatistical is calculated using deviation from expected slope of 1 and 
observed standard error of the slope. Meanwhile, tcritical is a tabulated value from required CI and 
degrees of freedom.41,42 In cases where tstatistical > tcritical (P < 0.05), deviations from expected 
results are statistically significant. As observed in Table 2.2 the only recoveries from 
immunoarray are statistically similar to true spiked concentrations (P > 0.05). ELISA recoveries 
are statistically different at P = <0.00001. These results further showed presence of systematic 
error in the ELISA method. 
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Linear Regression Plot Slope ± SD y-intercept ± SD  (ng mL-1) 
t-test at 95% 
CI 
Immunoarray vs. Spiked level* 1.013 ± 0.020 0.1298 ± 46.86 no diff. 
ELISA vs. Spiked level* 0.4551 ± 0.0327 195.1 ± 75.3 Sig. diff. 
Table 2.2: Linear regression t-test for spiked sample correlation plots. On accurate and precise 
measurement, the correlation plot will have slope of 1 and y-intercept of 0. Immunoarray shows 
statistically similar values to expected results, whereas ELISA does not have accurate recoveries 
for spiked samples. 
 
* n = 8, Null hypothesis is slope of correlation plot = 1. 
sig. diff. represents significantly different based on tstatistical > tcritical or P < 0.05 
no diff. represents statistically similar based on tstatistical < tcritical or P > 0.05 
 
 
2.4.3 Analysis of Bladder Cancer Patient Samples 
The microfluidic immunoarray protocol is utilized to analyze 41 serum samples from 
bladder cancer patients divided across four subsets: 10 samples from cancers-free control 
individuals, 11 from patients with low- grade tumors, 10 with high-grade tumors expressing no 
metastasis, and 10 samples from at least regionally metastasized high-grade tumors. The 
resulting immunoarray average CD62L protein levels (Figure 2.10A) are 367 ± 141 ng mL-1 for 
controls, 2243 ± 839 ng mL-1 for low-grade, 4551 ± 1662 ng mL-1 high-grade non-metastatic, 





Figure 2.10: Box plot analysis for 41 patient samples for four different subsets (1 = cancer free 
controls, 2 = low-grade tumors, 3 = high-grade non-metastatic tumors, and 4 = high-grade 
metastatic tumors): (A) Immunoarray (B) ELISA. Red dots represent individual recovered 
patient sample concentrations. Box top represents the mean and error bars are plotted at 1 
standard deviation of the mean. 
 
 
and yielded results that are significantly different for these samples, presumably related to the 
large errors found in the ELISA assay (Figure 2.10B). 
Box plots visualize trends in CD62L levels for the four subsets of patient samples for the 
electrochemical immunoarray and ELISA (Figure 2.10A-B). An ascending trend in circulating 
CD62L levels is observed concurrent with increasing severity of bladder cancer stage, with the 
exception of high-grade metastatic tumors for which CD62L levels in serum are lower than for 
high-grade non-metastatic tumors. The box plots indicate minimal overlap between the pooled 
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sample data for the individual sample subsets and t-tests confirmed that each subset had 
statistically different means at 95% confidence (Table 2.3).   
 
 
Assay type Assay type t-test at 95% CI 
Cancer-free controls vs. All Cancers 
Immunoarray Sig. diff. 
ELISA Sig. diff. 
Cancer-free controls vs. Low-Grade 
Immunoarray Sig. diff. 
ELISA Sig. diff. 
Cancer-free controls vs. 
High-Grade Non-Metastatic 
Immunoarray Sig. diff. 
ELISA Sig. diff. 
Cancer-free controls vs. High-Grade Metastatic 
Immunoarray Sig. diff. 
ELISA no diff. 
Low-Grade vs. High-Grade Non-Metastatic 
Immunoarray Sig. diff. 
ELISA Sig. diff. 
Low-Grade vs. High-Grade Metastatic 
Immunoarray Sig. diff. 
ELISA no diff. 
High-Grade Non-Metastatic vs. 
High-Grade Metastatic 
Immunoarray Sig. diff. 
ELISA Sig. diff. 
Table 2.3: Two sample mean t-test to differentiate patient sample subsets. P-value < 0.05 
suggests the difference between subset averages is statistically significant, i.e. the test can 
differentiate between the two subsets based on CD62L concentration. 
 
n = 10 for cancer-free controls patient subset, n = 11 for low-grade tumors subset, n = 10 for 
high-grade non-metastatic tumors and n = 10 for high-grade metastatic tumor subset.  
Null hypothesis is set as: 
mean of patient sample subset 1 = mean of patient sample subset 2. 
sig. diff. represents significantly different based on tstatistical > tcritical or P < 0.05 
no diff. represents statistically similar based on tstatistical < tcritical or P > 0.05 
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The null hypothesis is set such that the average recovered CD62L concentration for 
subset 1 = subset 2. In this case, tstatistical > tcritical (P < 0.05) signified statistically relevant 
difference between the recovered CD62L concentrations for the subsets under consideration, i.e. 
the method is able to distinguish between the two patient sample subsets. From Table 2.3, both 
assay detection methods distinguish tumor grade based upon circulating detected CD62L, with 
the exception of ELISA for control vs. high-grade metastatic as well as low-grade vs. high-grade 
metastatic tumors. Thus, the previous report of higher CD62L serum levels in metastatic vs. non-
metastatic bladder cancers7 is possibly biased by the systematic ELISA error. Although both 
assay detection methods differentiate between patient sample subsets, the immunoarray method 
performs at a higher confidence level (PImmunoarray << PELISA). The immunoarray analyses of 
serum samples from bladder cancer patients show a clear up-regulation in circulating CD62L 
levels progressing from controls to non-metastatic low-grade to non-metastatic high-grade 
cancers.  
Receiver-operator characteristic (ROC) plots on the patient sample data are done to 
assess diagnostic utility. Here, sensitivity (true positive rate) is plotted against 100-specificity 
(false positive rate) for a series of concentration thresholds. An assay with perfect discrimination 
has a ROC curve that has 100% sensitivity and specificity).43 The area under a ROC curve 
(AUC) quantifies the overall ability of the test to discriminate between individuals in 2 different 
classes, e.g. with and without cancer. Data with zero false positives and zero false negatives has 
an AUC of 1.00. ROC plots are obtained (Figure 2.11) for all pair combinations of patient 
sample subsets to obtain corresponding sensitivity and specificity values, AUC, and optimal 
concentration thresholds. Sensitivity ≥ 70%, specificity ≥ 70%, and AUC ≥ 0.50 are obtained for 





Figure 2.11: Receiver operating characteristic (ROC) curves comparing (A) cancer free-controls 
vs. all cancer patient samples, (B) controls vs. low-grade tumors, (C) controls vs. high-grade 
non-metastatic tumors, (D) controls vs. high grade metastatic tumors, (E) low-grade vs.  
high-grade non-metastatic tumors, (F) low grade vs. high-grade metastatic tumors, and  












ROC Comparison Assay type Sensitivity Specificity AUC Criterion 
Cancer-free controls 
vs. All Cancers 
Immunoarray 93.55 100.0 0.958 > 649.7 
ELISA 74.19 80.00 0.787 > 873.8 
Cancer-free controls 
vs. Low-Grade 
Immunoarray 100.0 100.0 1.000 > 649.7 
ELISA 81.82 80.00 0.836 > 873.8 
Cancer-free controls vs. 
High-Grade Non-
Metastatic 
Immunoarray 100.0 100.0 1.000 > 649.7 
ELISA 90.00 100.0 0.980 > 1291 
Cancer-free controls vs. 
High-Grade Metastatic 
Immunoarray 80.00 100.0 0.870 > 649.7 
ELISA 40.00 80.00 0.540 > 873.8 
Low-Grade vs. High-
Grade Non-Metastatic 
Immunoarray 90.00 90.91 0.918 > 3010 
ELISA 90.00 90.91 0.909 > 1401 
Low-Grade vs. High-
Grade Metastatic 
Immunoarray 100.0 72.23 0.809 ≤ 1783 




Immunoarray 100.0 100.0 1.000 ≤ 1783 
ELISA 90.00 90.00 0.940 ≤ 1338 
Table 2.4: ROC analysis parameters for patient sample subsets. Immunoarray has consistently 
more accurate performance in patient sample subset differentiation compared to ELISA. The 
criteria concentration value is selected at the best sensitivity and specificity when multiple 
differential concentration criteria points are available. 
 
n = 10 for cancer-free controls patient subset, n = 11 for low-grade tumors subset, n = 10 for 
high-grade non-metastatic tumors and n = 10 for high-grade metastatic tumor subset.  
Perfect patient sample subset discrimination will have sensitivity = 100%, specificity = 100%, 
and AUC = 1.0. 
The criterion value is the discriminating concentration of CD62L, above or below which the 





Significant differences are found by two sample mean t-test (P < 0.05, Table 2.3) for all 
subsets comparisons, except for cancer-free controls vs. high-grade metastatic and low-grade vs. 
high-grade metastatic for ELISA.42 Importantly, both immunoarray and ELISA are able to 
differentiate between low-grade and high-grade lesions, prior to metastasis  
(sensitivity = 90%, specificity = 91%, Table 2.4), despite systematic errors in the ELISA assay. 
However, metastatic samples could not be distinguished from low or high-grade non-metastatic 
cancers since serum CD62L levels are lower in the metastatic samples. Clearly, the immunoarray 
protocol provides better sensitivity and specificity compared to the ELISA kit. Consequently, the 
Immunoarray detection provides better discrimination between the different tumor 
classifications. 
2.4.4 Comparison of Patient Sample Results for Immunoarray and ELISA   
Immunoarray results for circulating CD62L levels are plotted against standard ELISA 
results for the 41 patient samples (10 healthy and 31 cancer samples). A linear correlation plot 
produces a slope of 2.764 ± 0.283, y-intercept of -1208 ± 371, and R2 = 0.710, as seen in  
Figure 2.12. Since immunoarray accuracy is already verified (Figure 2.9B-C), this plot further 
confirms that the ELISA kit underestimates CD62L levels in serum A correlation plot of 
immunoarray vs. ELISA recoveries for spiked samples shows results similar to the patient 
sample correlation plot (as seen in Figure 2.12, Table 2.5), indicating that systematic errors in the 
ELISA are also observed during patient sample analysis. These results are statistically different 
from expected linear correlation (slope = 1 and y-intercept = 0), when subjected to linear 
regression t-test (as per above procedure) at 95% CI (P < 0.05)  (Table 2.5) and at 90% CI (data 
not shown).  
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Figure 2.12: Linear correlation plots for Immunoarray vs. ELISA results for detection of CD62L 
in serum samples from patient samples. ELISA underestimates patient sample CD62L levels, as 
seen by slope = 2.76. 
Linear Regression Plot Slope ± SD 
y-intercept ± SD  
(ng mL-1) 
t-test at 95% 
CI 
Spiked sample recoveries§ 
Immunoarray vs. Spiked level* 
2.157 ± 0.169 -373.0 ± 201.0 Sig. diff.* 
Patient sample recoveries‡ 
ELISA vs. Spiked level* 
2.764 ± 0.283 -1208 ± 371 Sig. diff.* 
Table 2.5: Linear regression t-test for spiked sample and patient sample correlation plot. Both 
plots have statistically similar slopes and y-intercepts, indicating that systematic error in ELISA 
equally affects both spiked sample and patient sample analysis.  
 
§ n = 8 for spiked sample correlation plot, ‡ n = 41 for patient sample correlation plot.  
Null hypothesis is slope of correlation plot = 1.  
* represents statistically similar systematic error between the patient sample recoveries and  
   spiked sample recoveries, by linear regression t-test.  
sig. diff. represents significantly different based on tstatistical > tcritical or P < 0.05.  
no diff. represents statistically similar based on tstatistical < tcritical or P > 0.05 
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Furthermore, linear regression is also plotted for spiked sample recoveries  
(Figure 2.12B). A mean t-test for the two regression slopes yield P = 0.2196 at 95% CI and since 
P > 0.05, systematic error in CD62L ELISA is uniformly present in both spiked and patient 
sample analysis, as noted in Table 2.5. Moreover, similar to patient sample correlation, spiked 
samples correlation plot different significantly from expected linear plot with slope =1 and  
y-intercept = 0. 
2.5 Discussion 
Results show that a newly optimized bead-based microfluidic immunoassay for CD62L 
gave much better accuracy and sensitivity than ELISA (Figure 2.9, Figure 2.11, Figure 2.12; 
Table 2.1Table 2.5). Most serum protein ELISAs are reliable and are often used as referee assays 
to compare to newly developed methods for protein measurement. However, results reported 
here suggest the importance of verifying the accuracy of each ELISA method as well, before 
using it as a reference method. In the present case, the CD62L ELISA significantly 
underestimated CD62L levels outside the serum concentration range of 350 - 1500 ng mL-1. 
Results from spiked sample analyses and correlation plot slopes (Figure 2.9, Figure 2.12) are 
further analyzed with the one sample mean t-test, two sample mean t-test, and linear regression 
(Table 2.1-2.5), and confirm systematic error in ELISA in both spiked and patient sample 
analysis as do Figure 2.9 and Figure 2.12. These errors affect spiked sample recoveries (Figure 
2.9) and patient sample analysis (Figure 2.12) equally.  
The recovered concentrations for patient samples from ELISA had a bias in low  
(< 350 ng mL-1) and high concentration ranges (>1500 ng mL-1), thus partially masking clear 
distinction between the four patient sample classes as (Figure 2.10). In contrast, recoveries with 
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the bead-based microfluidic immunoassay provide accurate estimates of circulating CD62L 
levels in patient serum samples. Extensive statistical analyses strongly support the reliability and 
accuracy of the new microfluidic CD62L immunoarray. Additionally, the immunoarray’s 
dynamic range can be easily modified to suit the relevant concentration range of the samples by 
modulating the number of HRP labels and antibodies on the magnetic beads. The immunoarray 
protocol provides the additional benefit of allowing a single dilution factor over the entire 
dynamic range. Due to higher sensitivity and good accuracy, this semi-automated microfluidic 
assay module provides a promising tool with low technical burden for protein CD62L in a short 
assay time of 30 mins using low patient sample volumes. 
High CD62L gene and cellular expression reported previously supported a substantial 
increase in soluble CD62L protein expression with increasing stage of the disease.7  
We observed a distinct elevation in circulating CD62L protein level between low-grade and 
high-grade tumor patients prior to metastasis for both methods, while our immunoassay provided 
a sharper differentiation between the various sample sub-groups. Since the number of patient 
samples is relatively small, and no data is available on patient outcomes subsequent to sample 
collection, results provided here are still clinically inconclusive concerning diagnostic utility of 
CD62L. Further studies with larger sample size and accurate timeline of clinical outcomes are 
warranted to evaluate the performance of this more accurate and reliable method for 




A sensitive, accurate bead-based immunoarray method for detection of CD62L is 
documented with tunable dynamic range by optimizing the number of enzyme labels on 
magnetic beads. Accurate detection of circulating CD62L revealed increasing levels of CD62L 
from low-grade vs. high-grade lesions in bladder cancer, and if fully verified may offers serum-
based test for bladder cancer staging. Panels of biomarkers could also be investigated with this 
methodology in future to enhance diagnostic power for staging and grading bladder cancer. 
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  Chapter 3
Inkjet Printed Optical Phase Tags for Improved Counterfeit Detection  
3.1 Abstract 
An Optical Phase Tag (OPT) is fabricated by deposition of Zinc Oxide (ZnO) pattern on 
Aluminum (Al) substrate. A prototype OPT is inkjet printed on an integrated circuit (IC) in the 
shape of a quick-response (QR) code. This unique and low-cost OPT with a simple, yet elegant 
fabrication process makes the tag more secure and less likely to be breached by an attacker. 
Moreover, the controlled quilt building and layering process allows OPT to securely store 
valuable information about an object, such as a data sheet or a 3D image object. Nano-materials 
are applied for fabrication of these QR codes allowing customization of optical signatures. To 
authenticate the OPT, a two-step verification process is used: Polarimetric readings, and reflected 
light measurements. Material is inspected by illuminating the OPT with a coherent, linearly 
polarized light, analyzing the polarimetric readings, and computing the Stokes parameter. The 
second step involves using a coherent light source to illuminate the OPT and recording reflected 
light. This distinct signature is authenticated using nonlinear correlation. The two-step 
authentication process can successfully authenticate a true OPT, while providing a protocol for 
detecting counterfeit OPTs. Additionally, the fabrication process can be adapted to versatile 







Counterfeit goods have a devastating effect on an economy, or even cost lives in case of 
counterfeit medicines. The U.S. government and the WHO has reported on increasing access to 
counterfeit medication as an emerging threat that goes beyond loss of revenue,  
to increased burden on the healthcare system and even loss of lives.1,2 Besides medications, 
electronic parts and consumer goods are large contributors to the counterfeit markets 
worldwide.3 Electronic counterfeiting can have far-reaching impact, especially in the aviation, 
defense, or aerospace industry.4 Global value of counterfeit and pirated products is expected to 
reach $2.3 trillion by 2022, according to the International Chamber of Commerce.5 The 
counterfeit market has a complex supply chain and has even crossed over into legitimate 
distribution, which prevents simple regulation measures from being effective.1,2  
Improving counterfeit detection and manufacturing portable detection tools has attracted 
considerable research in recent years, with the market value predicted at $5.3 billion by 2025.6 
Common anti-counterfeiting strategies for electronic goods and components, such as analog, 
microprocessor or memory integrated circuits (ICs), transistors, include inclusion of tracking 
device or affixing tags or barcodes (that can be read with portable scanners) on to the packaging 
or the actual goods.7–9 Tuyls and Batina7 developed an anti-cloning strategy for the market 
available radio frequency identification (RFID) tags, which can be used for electronic tracking of 
a shipment. Physically unclonable functions have also been explored as a counterfeit detection 
method.10 Romero et al11 developed a protocol for quantifying the electromagnetic signature of 
these RFID tags as an anti-counterfeiting measure. However, these methods are expensive due to 




generating safety checks. Nevertheless, the visual code is easy to scan, hack, and replicate. To 
enhance effectiveness against counterfeiting, optical phase tags (OPT) have been recently 
introduced.8,9,12–14 An OPT made of Scotch tape is placed on an IC using customized thin film 
deposition and lithography: Polarimetric measurements are added to the authentication process 
reducing possibility of fraud.12 OPTs containing gold and other nanoparticles are also embedded 
in a quick-response code.8,13 The polarization characteristics are examined using transmission 
mode setups; thus, no investigation is made into these OPTs placed on an object, such as an IC. 
Selection of materials used to print the OPTs is crucial in establishing a sound, 
error-proof authentication process. Nanomaterial synthesis with shape and size selection can alter 
optical and conductive properties. Fabricating OPTs from such materials will provide customized 
optical systems, supplementing design of such low-error easy authentication tags.15,16 ZnO ink is 
used to fabricate the tags in this following study: ZnO nanoparticles are a well-studied 
nanoparticle system with excellent control over optical properties and cheap synthesis 
protocols.17–19 These printing inks can be further modified by introducing a) change in shape and 
size of particles15, b) doping with metals, c) change in physical color manifestation by addition 
of a dye. Inkjet printing can easily fabricate customized QR code patterns for the OPTs by 
deposition of the ZnO ink; smooth adaption of this process to any target substrate makes it 
suitable for broad application purposes.20,21  
Light waves have an associated electrical and magnetic field that is present in all  
x- and y- directions in case of non-polarized light. When light is polarized, the electrical wave is 
constrained to a single plane within the x- and y-axis. As light interacts with the surface, the 
reflected light can have different polarization from incident coherent light. This change is 




Stokes parameters is a set of values describing the polarization of an electromagnetic radiation 
accounting for individual parameters, i.e. total intensity, degree of polarization, shape parameters 
of the polarization circle or ellipse.22 Degree of polarization quantifies how much of the incident 
light is polarized, from the Stokes parameters. Other than polarization, reflected light also has a 
unique speckle pattern, or the intensity image formed from interaction between light waves 
reflected off the object’s surface. This noise-like pattern provides information about a material 
and can serve as a fingerprint as the light reflects differently due to the unique surface structure 
of the material. According to Goodman,22 it can be reasonably assumed that the light reflected 
from surface is complex Gaussian. Thus a correlator function can be used to visualize the speckle 
pattern as a peak. 
In this work, a two-step authentication scheme to determine the authenticity of an OPT is 
presented. An OPT of ZnO nanoparticles in inkjet printed on Aluminum (Al) coated substrate in 
the shape of a quick-response (QR) code. The fabrication of such tag directly onto an IC is also 
discussed. This unique OPT is then authenticated using a two-step scheme. First, material 
inspection is performed on the OPT by examining the polarimetric signatures of the OPT, under 
an incident coherent light, and computing the stokes parameters.23,24 The recorded pattern can 
then be authenticated using non-linear correlation.25 Moreover, we show that by using the two-
step authentication system, we are able to successfully verify the authenticity of an OPT and its 
material composition. To the best of our knowledge, this is the first report of fabricating a 







3.3.1 Chemicals and Instruments  
Zinc acetate (Zn(CH3COO)2), copper acetate (Cu(CH3COO)2), nickel oxide (NiO), 
ethylene glycol (EG, (CH2OH)2), ethanol (EtOH, CH3OH) are purchased from Sigma Aldrich 
(St. Louis, MO, USA). Common household Aluminum foil is purchased from a generic grocery 
shop. ICs are obtained from Analog Devices, and Intel. A Dimatix DMP-2800 Materials Printer 
from FUJIFILM Dimatix, Inc. (Santa Clara, CA, USA) is used for inkjet printing. Savannah 100 
Atomic Layer Deposition System from Veeco Instruments (Waltham, MA) is used for aluminum 
layer deposition on ICs. Optical analysis is performed using a linearly polarized green laser 
diode light source, a neutral density filter, and a Canon EOS 5D Mark II camera, and a CCD.  
3.3.2 Preparation of ZnO inks 
The ZnO ink is prepared according to a previously reported method with modifications.23 
In a typical synthesis, 0.5 M Zn(CH3COO)2 solution is prepared in EG by heating at 110 °C for 
½ hr to prepare a transparent solution. Once the solution is cooled to room temperature, EtOH is 
added to optimize the viscosity and the surface tension of the prepared ink (see Table 3.1). 
Filtration of the solution provides a clear and homogenous ZnO solution, with molal 
concentration at ~ 0.33 M, viscosity of 10-13.5 cP, and surface tension of 36-38 dyne cm-1. 
Doped ZnO solutions are prepared by addition of 10% Cu(CH3COO)2 and 10% NiO dopants 
prior to filtration. The final solvent compositions of doped inks are also optimized (see Table 













1 No 4 : 1 49.435 (4.560) 34.863 (0.448) 
2 No 2 : 1 13.489 (0.732) 37.881 (0.924) 
3 No 1.5 : 1 7.222 (0.660) 33.927 (0.564) 
4 10 % Cu 2 : 1 9.931 (0.465) 36.241 (0.657) 
5 10 % Ni 1.75 : 1 10.734 (0.539) 34.292 (2.161) 
 
Table 3.1: Pure ZnO inks are optimized for inkjet printing at suggested viscosity and surface 
tension ranges of 10-12 cP and 32-42 dyne cm-1 respectively. Final solvent composition of the 
ink for printing is selected at 2:1 EG:EtOH (in bold). With this benchmark, the 10% Cu and 10% 
Ni ion doped inks are optimized for final solvent composition of 2:1 and 1.75:1 EG:EtOH 
respectively (in italics). Errors for viscosity and surface tension are shown in parenthesis. 
 
3.3.3 Substrate Selection and Optimization  
Initial substrate optimization is required to achieve high surface adhesion, improving 
longevity of the OPTs. Glass, Kapton, untreated Aluminum (Al) foil, and NaOH-treated Al foil 
are tested for ZnO adhesion. Due to its hydrophilic surface, both untreated and NaOH treated Al 
foil show better adhesion for ZnO inks, in contrast to hydrophobic polymeric and glass 





3.3.4 Fabrication of QR Code Prototypes 
The datasheet for the IC (Figure 3.1A) is encrypted using the full-phase  
double-random-phase encryption (DRPE) (Figure 3.1B-C) with photon-counting (PC-DRPE)  
(Figure 3.1D), after assessing many different encryption algorithms.22,26–28 Once the image is 
encrypted, the image is vectorized and Huffman coding is iteratively applied until the image 
sequence is sufficiently small and able to be stored in a QR code (Figure 3.1E).29  
After printing was optimized for Al foil, OPT is printed on a commercially available IC.  
ICs are first coated with a thin Al layer (~ 100 nm thickness) by physical vapor 
deposition. QR code with 25 % or Q-level error allowance is designed online with QR code  
2D barcode generator (RACO industries) (Figure 3.1F). The pattern is edited to 1040 dpi 
resolution and 1.0 cm x 1.0 cm size, and printed with a customized waveform and drop spacing 
of 15 µm using a Dimatix DMP-2800 Materials Printer. The printed patterns are annealed at 
200°C for 1 hr to ensure total conversion to ZnO and solvent evaporation prior to optical 
analysis, as seen in Figure 3.1G.  
Upon optimization of doped ZnO inks, 2D and 3D quilt patterns are designed as true and 
false class. 2D quilt pattern is printed such that specified areas of the QR code are printed with a 
combination of the undoped ZnO or Cu/ Ni doped inks in a quilt pattern, as illustrated in  
Figure 3.2A. The 3D quilt is fabricated by sequentially printing with different inks for each layer 
(see Figure 3.2B). The true and false class QR codes will differ by placement within a single 









Figure 3.1: Generation and fabrication of an OPT on Al-coated IC. An IC datasheet (A) is 
encrypted with DRPE (B-C) and PC-DRPE (D). The image is then vectorized and Hoffman 
coding is applied till a small sequence is generated (E). A QR code is designed (F) using an 
online QR code 2D barcode generator (RACO industries). The OPT is inkjet printed (G) as a QR 






Figure 3.2: (A) 2D and (B) 3D quilt pattern QR code prototypes depict the different ways true 
and false class codes may be fabricated. (A) 2D quilt is fabricated by printing specified areas 
with patches of pure ZnO ink and the rest with doped ink (e.g. 10% Cu doped ZnO ink). The 
placement of doped ink will differ between true and false class. (B) 3D quilt is fabricated by 
printing successive layers of either pure or doped ZnO ink. The true and false classes of QR 




3.3.5 Authentication of QR Codes 
The two-step authentication process for the OPTs includes polarimetric signature and 
speckle pattern signature. For both set of experiments, the optical setup consisted of a coherent 
laser light being incident on the OPT material and the reflected beam being captured by a CCD 
camera (Figure 3.3A-D). A neutral density filter is used to reduce the intensity of the laser diode. 
For polarimetric signature, a polarizer is added in the path of reflected light (Figure 3.3A-B). A 
resolution of 5616 x 3744 pixels and sensor size of 36 mm x 24 mm is used for detection, with 
an exposure time is set to 0.033 ms, F/# of 2.5 and ISO level of 5000. 
Polarimetric signatures are recorded and Stokes parameters and the degree of polarization 
are calculated to characterize the OPT material composition. Degree of polarization can be 
computed by placing a polarizer in front of the recording sensor and analyzing intensity of 
recorded light, as shown in Figure 3.3A-B. The polarization is rotated 00, 450, 900, and 1350 with 
respect to the x-axis of the cartesian coordinate system. Speckle pattern is captured directly by 
the camera without a polarizer, as illustrated in Figure 3.3C-D. Intensity of these patterns is 
recorded over time as many different speckles are imaged and their intensity decreases with 
time.27 Image authentication is performed by applying k-th order nonlinear filter with k = 0.3 and 







Figure 3.3: Experimental setup for polarimetric readings (A-B) and speckle pattern capture  
(C-D). (A) Schematic and (B) experimental optical setup for polarimetry consists of a green laser 
diode incident on the object. The reflected light is then passed through a polarizer and recorded 
by a CCD. For speckle authentication, (C) schematic and (D) experimental optical setup is 





3.4 Results  
3.4.1 Characterization of Pure and Doped ZnO Inks 
Inkjet printed blocks of pure and doped ZnO inks are analyzed by transmission electron 
microscopy (TEM) for visual examination of effect of doping on the ZnO ink (Tecnai 
T12S/TEM, Thermo Fisher Scientific, Hillsboro, OR, USA), as seen in Figure 3.4A-C. The 
morphology observed for pure ZnO showed hexagonal structures ~ 20 nm in size. On doping 
with Cu and Ni, flat rectangular morphology is observed. Cu doped ZnO ink showed higher 




Figure 3.4: TEM images of (A) Pure ZnO, (B) 5 % Cu doped ZnO, and (C) 5 % Ni doped ZnO 
ink. The change in morphology, i.e. size and shape, of the crystals indicates that optical 






3.4.2 Scanning QR Codes 
Consistent fabrication of OPTs is achieved by selected printing method. The QR code is 
successfully scanned with either of two imaging methods: Simple scan by a generic smartphone 
QR code scanner app is able to read the encrypted number sequence, if enough contrast is 
present between the code and the IC. Otherwise, the code is simply imaged using the Canon EOS 
5 camera, enlarged on a computer screen, and read using a smartphone app. A true-class OPT is 
defined as a error-free printed QR code on an Al-coated IC, as seen in Figure 3.5A: This will be 
referred to as OPT 1. OPT 1 is scanned (see Figure 3.5B), reading the encrypted and compressed 
data matching that from Figure 3.1E. This information is then decompressed and decrypted to 
yield a noise-like image (Figure 3.5C). For purpose of visual authentication, non-linear 
correlation using the k-th order nonlinear filter with k = 0.3. A significant peak is observed, 
normalized to 1 (Figure 3.5D), indicating an authentic image.  
Moreover, a false class datasheet is used to authenticate the image, shown in  
Figure 3.6A. The k-th order nonlinear filter is then used this image as an input with no resultant 
significant peak indicating a false class image (Figure 3.6B). The output is normalized relative to 








Figure 3.5: (A) Enlarged OPT, denoted as OPT1, printed on an IC and (B) Scanned OPT.  
(C) Decrypted image followed by (D) Authentication using the k-th order nonlinear filter, with k 







Figure 3.6: (A) False image, a datasheet for an IC of different brand is transformed through the 
k-th order nonlinear filter, with k = 0.3. The image on normalization relative to the true class 
image peak, gave a maximum peak of 0.03 (B). 
 
3.4.3 Authentication of OPTs with Polarimetry 
A typical polarization signature for a true class OPT is shown in Figure 3.7A-D, wherein 
true class image is the OPT 1 as seen in Figure 3.5A. The Degree of Linear Polarization (DoLP) 
is also calculated to assess the OPTs fabrication (Figure 3.7E). The average DoLP for true class 
QR code is 0.5654 with a standard deviation of 0.0459 (Table 3.2). Moreover, the serial number 
of the IC has an average DoLP of 0.45050 with a standard deviation of 0.0467 and the DoLP of 
the QR code with Al missing is 0.4634 with a standard deviation of 0.0281 (Table 3.2). These 








Figure 3.7: Polarimetric readings for OPT 1 corresponding to (A) 0o, (B) 45o, (C) 90o, and (D) 







DoLP image Average DoLP Standard deviation 
OPT 1 0.5654 0.0459 
Serial no. on OPT 1 0.4505 0.0467 
Al missing from OPT 1 0.4634 0.0281 
OPT 2 0.5671 0.0314 
Al missing from OPT 2 0.4199 0.0398 
OPT 3 0.5987 0.0539 
OPT 4 0.3063 0.0539 
 
Table 3.2: DoLP is studied for an array of true and false class OPTs. Good correlation is found 
in areas where OPT is correctly printed. DoLP is seen to vary from average value of true class 
upon damage to or change in printing and handling of the OPT. 
 
False class OPTs are analyzed with polarimetry for comparison: One is partially printed 
on the non-Al coated IC, another is degraded, and a third is annealed for longer than 1 hr turning 
the print white (Figure 3.8A,C, and E). The polarimetric signatures for these fabricated OPTs 
demonstrate the robustness of material inspection for the OPT tag authentication scheme (Figure 
3.8B, D, and F). The QR code partially deposited on non-coated IC or OPT 2 has average 
polarization of the QR code is 0.5671 with a standard deviation of 0.0314 (Table 3.2), despite the 
absence of serial number in the background (see Figure 3.8B). The top right corner is printed 
direct on the IC circuit and has an average DoLP of about 0.4199 and standard deviation of 







Figure 3.8: Tampered QR codes or “false class” OPTs are compared to OPT 1 as “true class”. 
(A) Partially printed OPT on non Al-coated IC (OPT 2), (B) the DoLP image of OPT 2. (C) A 
degraded OPT (OPT 3) and (D) its DoLP images are studied. (E) OPT whose color has changed 





Degraded OPT has average DoLP of 0.5987 with a standard deviation of 0.0539 (Table 3.2). 
Lastly, OPT with the color changed to white (Figure 3.8E), referred to as OPT 4, has average 
DoLP is 0.3063 and standard deviation of 0.0539 (Table 3.2). As white is a highly reflective 
material, the DoLP is highly unpolarized as reflected by the DoLP value. 
3.4.4 Authentication with Speckle Pattern 
The second part of the classification scheme involves observing the speckle signature of 
the OPT. Authentication is performed using the k-th order nonlinear filter. To evaluate the 
performance of the system, the peak-to-output energy metric is used. This metric is defined as: 
!"# = ! ! !,!
!
! ! !,! ! ,                                             (1) 
 
where POE denotes peak to correlation energy, E[.] denotes expected value, E[|y(τ,τ)|]2 denotes 
the energy of the peak and ! ! !, ! !  denotes the energy of the scene. 
Figure 3.9A depicts the speckle signature when OPT 1 (see Figure 3.5A) is illuminated 
with a green laser diode. Green color channel is used for captured images.  
The k-th order non-linear filter is used for authentication using k = 0.3. A significant peak is 
observed indicating an authentic signature (Figure 3.9B). Note that the output is normalized to 1. 
Moreover, the POE is 2434. A false class speckle signature is inputted into the system, shown in 
Figure 3.9C, obtained from OPT 2 (Figure 3.6A). The output of the correlator shows no 
significant peak and the POE is significantly lower with a value of 0.6504 (Figure 3.9D).  
The classification is also examined with x-axis translation, wherein object is moved  




0 mm translation, and steadily decreases when moved in either direction (data not shown).  
A practical implication of this study is that the distance of the CCD is from the object is 




Figure 3.9: (A) True class speckle signature obtained from OPT and (B) its authenticated pattern 
using the k-th order nonlinear filter with k = 0.3, normalized to relative intensity of 1. (C) False 
class optical signature pattern and (D) corresponding authenticated signal. Observed values for 







A robust fabrication and authentication method has been achieved with the current 
protocol of inkjet printing ZnO nanoparticles as a QR code on Al-coated ICs. The multi-step 
authentication process proves useful in eliminating even minor damages or changes in the 
fabrication process. The first point of inspection is the visual examination and scanning of the 
QR code. Damaged or worn off QR codes cannot be scanned successfully (Figure 3.10), such is 
the case of OPT 3 (Figure 3.8C). However, QR codes not printed fully Al-coated ICs or OPT 2 
(Figure 3.8A) or those that have turned white due to prolonged annealing or OPT 4 (Figure 3.8E) 
will still pass visual examination and scanning step (Figure 3.10). Thus, QR code scan alone is 
not able differentiate OPTs with minor non-conformance in the inkjet printing. 
The next authentication step includes analysis by polarimetry and computation of Stokes 
parameters and DoLP. This step enhances the authentication process by analyzing QR code’s 
material composition. It will pass QR codes that are printed by ZnO material and have similar 
deposition and physical appearance. Thus OPT 3 and OPT 4 will not pass inspection, however 
OPT 2 will as large portion of the QR code is printed on the Al-coated IC (see Figure 3.10).  
The final step in the authentication protocol measures speckle signature, which is 
indicative of surface roughness. As the Al-coating on the IC would contribute to overall surface 
roughness, this step is able to distinguish true image OPT 1 from false image of  
OPT 2 (Figure 3.10). Moreover, any other errors during the fabrication process will similarly fail 
the speckle signature authentication. Thus a simple and efficient authentication protocol is for 






Figure 3.10: Summary of authentication process for inkjet printed OPTs on Al-coated ICs. 
Physical appearance, damage to the print, change in annealing process, and other non-






A secure object authentication system has been presented that involves placing a unique 
optical phase tag (OPT), comprised of inkjet deposited ZnO nanoparticles on  
Al-coated integrated circuits. Moreover, the tag takes the form of a QR code, which stores 
critical information about an object, such as the data sheet. The authentication process has two 
major components: First step consists of material inspection and determining that the OPT has 
not been altered, changed or tampered. This is accomplished by illuminating the QR code with a 
coherent light source, and computing the Stokes parameters along with the degree of linear 
polarization. The next step is speckle authentication by illuminating the OPT with a coherent 
light source and capturing the reflected light, which is then authenticated using nonlinear 
correlation. The proposed technique is able to differentiate true class OPTs from false class. 
Future work includes creating a more compact system, different authentication algorithms, and 
OPTs consisting of more complex materials. 
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  Chapter 4
Inkjet Printed Electrochemical Sensor from a Novel Bronze Material and 
Multi-well Catalytic Reactor with Sol-gel Manganese Oxide Structures 
4.1 Abstract 
In this chapter, two applications of inorganic materials are explored: In part one, an 
electrochemical sensor is designed with a novel bronze ink and in part two, a design for  
3D printed multiplexed catalytic reactor is proposed. First, The bronze material is inkjet printed 
into an 8-electrode system that can facilitate fabrication of disposable electrochemical sensors. 
The 8-electrode design further enhances multiplexing capabilities by analyzing multiple analytes 
simultaneously. Future work will include characterization of the surface of electrodes and their 
electrochemical performance, and surface attachment of protein or antibodies for applications in 
biomarker detection. Secondly, a 3D printed catalytic reactor is designed to create wells similar 
to a 96-well plate, each of which can carry out electrocatalysis. The design incorporates a base 
plate, a counter electrode, a reference electrode, and inkjet printed manganese oxide.   
Future work includes printing and assembling the device and testing with common catalytic 
reactions, such as oxidation of alcohols. 
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Part I:  
Inkjet Printed Electrochemical Sensor from a Novel Bronze Material 
4.2 Introduction 
A variety of conductive inks are applied to the fabrication of inkjet printed electronics, 
including conductive polymers, molten metal, metal precursors, and metal nanoparticles.1–3  
Non-ambient printing conditions and post-print sintering at high temperatures make molten 
metal or metal precursor inks inefficient for manufacturing flexible electronics.2 Metal 
nanoparticles are often the best choice for conductive inks, due to room or low temperature 
printing and better conductivity than conductive polymers; however require some processing to 
form uniform, conductive lines.2,4  
An array of flexible electronics has been manufactured with inkjet printing, from single 
layer connectors,3,5,6 transistor and other components,7 to full multi-layer fabrication of a solar 
cell or a device.8–10 Advances in nanoparticle synthesis and printing methodology has reduced 
width of conductive ink tracks to < 25 µm, significantly allowing fabrication of smaller 
devices.6,11 Gold particles, 2-5 nm sized, are printed in a toluene solution for conductive tracks as 
narrow as 17 µm with laser sintering.11 Carbon nanotubes are also employed for conductive 
patterns in a water suspension and without post-print processing.12 Narrow (~ 40 µm) silver 
conductive tracks are inkjet printed by van Osch et al13 using 30 nm silver nanoparticles, with 
easier thermal sintering process. Our research group inkjet prints thiol gold nanoparticles  
8-electrode arrays, that are successfully used as biosensors for detection of protein cancer 
biomarkers.14,15 
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Gas sensors have also been developed by inkjet deposition of the sensing element, the 
electrodes, or even the entire sensor.16–18 Kukkola et al. fabricated tungsten based resistive and 
capacitive sensors for nitric oxide and hydrogen gas respectively by depositing the tungsten inks 
on silicon substrates with interdigitated platinum electrodes.16 Fang et al improved the sensitivity 
of a carbon nanotube-modified Kapton resistive diethyl ethylphosphonate sensor by chemical 
processing of inkjet printed silver interdigitated electrodes.19 The silver electrodes are partially 
replaced by porous gold layer on chemical treatment, producing a sensor with 5 times more 
sensitivity. 
More recently, efforts are directed towards producing fully inkjet printed sensor 
surface.20–24 In 2010, Wang et al designed a heat sensor by printing layer of sol-gel zinc oxide 
solution and of the top silver electrode on a flexible aluminum sheet as the bottom electrode.20 
The oscilloscope connected to the system registers a voltage output on introduction of proximal 
heat source, providing an inkjet printed disposable heat sensor. Since then, a sol-gel based tin 
oxide sensor, a copper oxide sensor for carbon monoxide, and a copper acetate sensor for H2S 
are also developed entirely with inkjet printing.22–24 
4.3 Experimental 
4.3.1 Chemicals and Instruments 
2-hydroxyethyl cellulose, ethylene glycol (EG, (CH2OH)2), ethanol (EtOH, CH3OH), and 
Tween-20 are purchased from Sigma-Aldrich (St. Louis, MO, USA). 18 MΩ·cm purified water 
(H2O) is used as needed, by passing house-distilled water through a Hydro Service and Supplies 
purification system (Durham, NC, USA). Precursor mixture and final bronze product  
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is provided Suib group, UConn.25 Inkjet printing is performed with Dimatix DMP-2800 printer 
(Fujifilm Dimatix, CA, USA). Surface tension measurements are made with Pendant Drop 
Tensiometer OCA 20 (Future Digital Scientific Corp., NY, USA) and viscosity measurements 
with ARES-G2 (TA instruments, DE, USA). 
4.3.2 Ink and Substrate Optimization 
Two inks, of either the precursors or the final bronze product, are optimized in EG/EtOH 
or H2O/EG solvent systems to achieve viscosity of 10-12 cP, surface tension of  
28-33 dyne/cm, and concentration of 100 mg ml-1. The bronze product ink is more suitable for 
printing and post-print processing, with final solvent composition at 1:2 H2O:EG.  
To stabilize the colloidal solution, the bronze nanoparticles in H2O/EG solution are sonicated for 
4 hours after addition of 1% w/v 2-hydroxyethyl cellulose. The ink is filtered through  
0.2 mm filter prior to inkjet printing. 
4.3.3 Fabrication of Immunoarray Sensor 
8-electrode arrays are printed with micro sensing area and contact pads as previous 
published and are sintered at 200 °C for 2 hours (Figure 4.1).14 Briefly, a clean 22 cm x  
28 cm Kapton sheet is placed in the Dimatix printer and platen vacuum is applied. Ink cartridge 
is filled with the bronze ink solution and waveform is customized till consistent ink droplets 
were formed. The pattern file is set to allow for printing multiple arrays in a single print, with 
varying spacing between arrays. The bronze nanoparticle ink is deposited onto the Kapton 






Figure 4.1: Pattern for 8-electrode electrochemical array. 
 
4.4 Results and Discussion 
Precursors inks are better stabilized in the ink solvent and printed on porcelain chips to 
assist with the required high temperature chemical reaction. Upon baking at 600 °C for  
2 hrs, the correct final product is not formed: Unequal jetting ratio of the three precursors may be 
responsible for this outcome. Hence, bronze colloidal solution is used as the conductive ink in 
1:2 H2O:EG solution. The print however is not consistent and printing cartridges were 
continuously blocked. Scanning electron microscopy is performed on the ink from a blocked 
cartridge (Figure 4.2); showing highly crystalline cubic structures > 200 nm in size. As this size 
exceeds the printing capabilities of the Dimatix printer, further ink processing for size reduction 
and better colloidal formation is required. The ink is then prepared in 1:2 H2O:EG solution with 
1% w/v 2-hydroxylethyl cellulose and sonicated at room temperature for 4 hrs. The ink is filtered 
through 0.2 µm filter prior to printing. While better print quality is observed, the ink still 






Figure 4.2: SEM of bronze product on printing without sonication. The size observed for the 
highly crystalline cubic structures is > 200 nm, thus being unsuitable for printing. 
 
4.5 Conclusion 
The bronze product proves to have better printing efficiency than the precursor mixture, 
although a stable colloidal solution of requisite size (< 200 nm) is yet to be consistently obtained. 
More ink optimization is required prior to printing electrodes. Once printed, electrodes will need 
to be characterized for surface area, morphology, electrochemically active area, conductance, etc. 




Part II:  
Multi-well Catalytic Reactor with Sol-gel Manganese Oxide Structures  
4.6 Introduction 
4.6.1 3D Printing Techniques 
3D printing fabrication is achieved by layer-by-layer assembly of materials to form a 
three dimensional structures. Numerous free and licensed software are available for designing 
models, such as 123design, CAD, and computer-assisted splicing of these models into layers.26 
Existing 3D printing methodologies predominantly employ deposition such as in Fused 
Deposition Modeling (or FDM), and/or curing of materials, like Stereolithography  
(or SLA), either in pure form or with additives that improve functionality of such materials.26,27 
Combinations of the two methods are also commercially available in Inkjet 3D Printing (3DP), 
Selective Laser Sintering (SLS), and Direct-write/ 3D plotting type 3D printers.26  
In Fused Deposition Modeling (FDM), a self-fusing, thermo-setting polymeric material, 
as a heated filament, is extruded in layers in FDM printers, much like the inkjet printers 
previously discussed. The most common filament materials are low-melting polymers, such as 
polycarbonate (PC), polylactic acid (PLA), acrylonitrile butadiene styrene (ABS). A low-cost 
option for 3D printing, this technique can print multiple filaments simultaneously provides 
capability of printing complex structures with required functionalities. While fast-paced, simple, 




2D layers are built by curing a photopolymer, such as epoxy or acrylic resins in 
Stereolithography (SLA). As a UV laser tracks a pattern on the printing platform, the resin 
polymerizes to form the layer. Following this curing method, platform is layered with fresh resin 
used to print the next layer. SLA provides very high-resolution prints, which can be made 
transparent by post-print treatment. Several parameters, such as rate of scanning, intensity of the 
laser, exposure time, addition of curing agents can affect thickness of individual layers, 
resolution and printing speeds. The main drawbacks of this technique are cost, and lower speeds 
of printing. 
Much like SLA, Inkjet 3D printing or 3DP is achieved by layer-by-layer curing. 
However, in 3DP, a powder is spread on printing platform, which is cured by inkjet deposition of 
a liquid binder to form the layer pattern. The cycle is repeated to yield the final model and the 
uncured powder is easily removed. Selection of powder and binder is key to achieving high 
quality prints. A fast printing method, 3DP can be performed at room temperature with versatile 
materials, although with low resolution. 
Selective laser sintering (SLS) uses powder processing as in 3DP, however the binder is 
replaced with a laser beam for curing. High power lasers generate localized heat, fusing together 
powder particles. Most of the advantages of 3DP carry over to SLS, however the printing 
technique is limited to select thermosetting plastics. Only polycaprolactone (PCL) and polyamide 
(PA) have been successfully used for SLS printing. Additionally, parameters such as powder 
size, laser power, speed and spacing of scans control resolution. 
3D plotting or direct-write employs a pressurized syringe to deposit viscous printing 
material in layers, as the syringe moves in X-Y-Z direction. Mixing two reactive materials prior 
to extrusion, heat, or UV light are typical curing methods. Quality of prints is affected by speed 
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of printing and material rheology. 3D plotting can be used with flexible materials, used in 
solution, paste, or hydrogel form. Temporary structure support may be needed to aid initial 
printing, before structural strength is achieved.   
4.6.2 Printed Catalytic Systems 
A few inkjet printing applications have been developed for fabrication of structures for 
improved catalytic efficiency. Busato et al28 deposited palladium catalyst on polyimide films to 
assist fabrication of interdigitated copper electrodes. Picoleter volumes of platinum catalyst was 
inkjet printed as membrane electrode assemblies by Taylor et al.29 A high throughput system for 
building catalytic libraries was designed by Liu and coworkers, which measure hydrogen 
evolution at different catalytic zones for compilation of activity data.30 Micro-channel reactors 
with inkjet printed nanoparticle-based catalysts are also fabricated and successfully used in 
methane steam reforming reaction.31  
3D printing has been incorporated into catalytic systems as mainly reactionware.32–34 
Symes et al32 “printed in” catalyst layer into the 3D printed reactionware, by loading the printing 
polymer with a paste of palladium and carbon. They were successful in hydrogenating styrene at 
room temperature within 30 mins, while the reaction without the catalyst showed no product in  
2 hrs. Kitson et al34 improved this design by a customized microfluidic build up, with catalytic 
chambers for specific reactions in a 3-step reaction, using both montmorillonite K10 Lewis acid 
and palladium/carbon paste as catalyst. Other works have directly 3D printed the catalytic 
mixture into the shape optimized for reaction chamber, such as the “woodpile” structure from 
copper/aluminum oxide ink35. 
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4.7 Experimental 
4.7.1 Chemicals and Instruments 
Toluene is purchased from Sigma-Aldrich (St. Louis, MO, USA). Inkjet printing is 
performed with Dimatix DMP-2800 printer (Fujifilm Dimatix, CA, USA). Surface tension 
measurements are made with Pendant Drop Tensiometer OCA 20 (Future Digital Scientific 
Corp., NY, USA) and viscosity measurements with ARES-G2 (TA instruments, DE, USA). 
Manganese oxide catalysts are provided by Suib group, UConn. 
4.7.2 Inkjet Printing of Manganese Oxides 
Manganese oxide catalysts, in particular, M-150, M-350, Mn2O3, are solubilized in 
toluene to achieve viscosity of 8-10 cP, surface tension of ~ 28 dyne/cm, and nanoparticle 
concentration of 100 mg ml-1. The ink is filtered through 0.2 mm filter prior to inkjet printing. A 
simple rectangular block pattern is printed on Kapton sheet to test print quality and adhesion to 
Kapton. Both are found to be reliably consistent. 
4.8 Design of Catalytic Reactor 
The catalytic reactor designed will mimic a 96-well plate used for high-throughput 
UV/Vis analysis (Figure 4.3). 3D printing will be used to fabricate the bottom plate and the well 
edges for the 96-well plate. Sandwiched between the two 3D printed components will be the 
catalytic structure. The substrate for the inkjet printed catalyst patterns will be polyamide film or 
similar inert polymeric film. If electrocatalysis is to be performed, a counter and reference 





Figure 4.3: Schematic of a high-throughput multi-well catalytic reactor includes inkjet printed 
catalyst structures sandwiched and sealed between 3D printed bottom plate and well edges.  
 
respectively, with appropriate contact pads for connections to an electrochemical workstation. 
No electrodes will be required if normal catalytic reaction is observed.  
The catalytic structures within each well can be custom designed for an array of catalysts 
under study, with each row or column dedicated to a single catalyst or a single reaction, etc. 
Inkjet printing patterns can be developed to optimize surface morphology of such catalysts, by a 
combination of patterns as illustrated in Figure 4.4. Wells with low or high surface area for a 
single catalyst can be designed (see Figure 4.4A-C). Two or more catalysts can also be printed in 
combination, with low (Figure 4.4D) or high (Figure 4.4E) overlap between the two catalysts.  
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The added benefit of such a system is the ability to conduct both regular and 
electrochemical catalysis. The well-plate format can be designed to suit specifications for a 
UV/Vis plate reader and thus can allow monitoring of the reaction by change in UV/Vis 
absorbance of reactants or products. The plate can also then suit parameters for robotic arm 
systems used for ELISA automation - ensuring progress to fully automated system for building 







Figure 4.4: Catalytic patterns can be customized for each well: (A) single catalyst, low surface 
area, (B) single catalyst, medium surface area, (C) single catalyst, high surface area, (D) two 





An integrated inkjet and 3D printed device for high-throughput catalysis is designed, a 
proof of concept study is presented with manganese oxide sol-gel materials as catalysts. The 
future work will include printing and assembling this device, upon which simple catalytic 
reactions can be screened for a prototype study. The design, upon completion, can provide a 
unique reactor that allows microliter sized reactions and easy analysis by UV-Vis for building 
catalysis library for the inkjet printed catalytic systems. 
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